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ABSTRACT 
Title of Abstract: Assessment of thrombotic and non-thrombotic troponin 
elevation (NTTE) 
Department: Cardiology 
Name of Candidate:  Pranay Anil Jain 
Degree and Subject: DM Cardiology 
Name of Guide: Prof. George Joseph 
Name of Co-Guide: Prof. Viji Samuel Thomson 
Aims: 
            Assessment of thrombotic and non-thrombotic troponin elevation (NTTE) 
Objectives: 
1) To correlate cardiac troponin T (cTnT) levels in critically ill non-cardiac 
patients (CINCP) and acute coronary syndrome (ACS) patients with duration of 
hospitalization, in-hospital and 30 days mortality. 
2) To describe the range of troponin elevation, positive and negative predictors for  
NTTE in CINCP stratified according to APACHE II score. 
Methods:  
            This is an observational cross sectional study done in department of 
Cardiology and Medicine (Critical Care division). 100 patients with ACS admitted in 
CCU/CPU and 100 CINCP (APACHE II score >12) with elevated cTnT levels 
admitted to MICU/MHDU were included in the study. Baseline sample of troponin 
was send within 24 hours of admission. Second set of cTnT and CKMB sample was 
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send within 24 hours of first sample. APACHE II score was calculated with-in 24 
hours of admission in MICU/ MHDU based on worst value up-to that point. 
Constitutional symptoms, risk factors for coronary artery disease, ECG, 
Echocardiography & renal parameters were documented. 
          The data for all groups will be expressed as mean ± SD. Descriptive analysis 
was used to find out number and percentages. Categorical values were reported as 
proportion and percentages and it was compared using Chi-Square test.  For 
continuous variables, mean with standard deviation was used and it was compared 
using independent sample t-test if normal and Mann-Whitney U test if not normal in 
Univariate analysis. The variables which were significant at Univariate analysis were 
taken for Multivariate analysis. Survival analysis was used to find association 
between in-hospital mortality and troponin levels in thrombotic ACS group and 
NTTE group.  
Results:  
             In this study troponin levels measured at baseline and within 24 hours of 
admission were significantly higher in patients who were admitted to MICU with 
ACS than with NTTE (373.04±1124.51 vs. 289.16±1062.26 and 743.31±1303.90 vs. 
258.62± 891.41 respectively; p value= 0.05 and 0.000 respectively). When a troponin 
level of >300 ng/L was considered along with electrocardiographic and 
echocardiography abnormality in the presence of chest pain, acute coronary syndrome 
could be diagnosed with a sensitivity of 100%, specificity of 77.59%, and Positive 
Predictive value of 76.36%. Critically ill patients with high troponin levels had early 
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in-hospital mortality. (Pearson co-relation coefficient = -0.068 and -0.072; p value 
0.501 and 0.479 respectively). In MICU group there was a positive trend toward 
increased mortality or re-hospitalization ≤ 30 days after discharge with elevated 
troponin T levels at baseline and within 24 hours of the first sample but this was not 
statistically significant (p value = 0.157 and 0.564). We found sepsis (77.59%), ARF 
(68.97%), anemia (43.10%), shock (31.03%), pneumonia (25.86%), ARDS (20.69%), 
myocarditis (12.07%), CHF (10.34%), tachyarrhythmia (6.9%), CPR (6.9%) as 
common causes associated with NTTE. 
Conclusion: 
               The study showed that baseline troponin level was significantly associated 
with in-hospital mortality. In CINCP patients with troponin value >300 ng/L along 
with chest pain, ECG and ECHO abnormalities; acute coronary syndrome could be 
diagnosed with reasonable accuracy. The commonest causes of NTTE were renal 
failure, anemia, sepsis and septic shock. 
Key words: Critically ill non cardiac patients, non thrombotic troponin elevation, 
ACS. 
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INTRODUCTION:  
                 In the assessment of patients presenting to emergency department with 
acute onset chest pain; troponins now play a major role in diagnosing acute coronary 
syndrome (ACS) and its management. Cardiac troponin denotes myocardial necrosis 
and does not always signify major coronary artery disease. Troponin level elevation 
indicates myocardial injury but in critically ill patients it may occur without evidence 
of myocardial ischemia and can lead to incorrect diagnosis of ACS (1-3). In patients 
admitted to Medical intensive care unit (MICU) about 50% of them have troponin 
elevation without ACS (4).  
               Damaged cardiac myocytes releases different proteins into the circulation, 
measurement of which we can recognize myocardial necrosis. Cardiac proteins such 
as cardiac troponin T (cTnT) and I (cTnT), CKMB, LDH, myoglobulin, 
myeloperoxide and many others are released into blood with myocardial necrosis (1). 
CKMB has been replaced as the gold standard by cardiac Troponins. For myocardial 
cell damage cTn is now the most sensitive and specific laboratory marker (4-6).   
                 There is no specific International Classification of Diseases 9 (ICD-9) code 
for severe extra-cardiac problems such as acute respiratory distress syndrome 
(ARDS), sepsis or septic shock causing myocardial injury as evidenced by transient 
cardiac biomarker’s elevations in serum. In the new Universal Definition of 
Myocardial infarction (MI) such conditions can be called as Type 2 MI (7).  Type 2 
MI in such patients can be a ‘working diagnosis’, as a coronary artery lesion was not 
totally excluded (8).  Troponin is a sensitive marker to rule out Non ST elevation 
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myocardial infarction, but it is less useful to rule in this event as it has less specificity 
(8). 
FIGURE 1: CARDIAC BIOMARKERS: APPROXIMATE SERUM LEVELS VS. 
TIME OF ONSET FROM ACS 
               In intubated or sedated patients with elevated serum troponin levels; 
symptoms cannot be used as a major guide for diagnosing ACS. Patients having pre-
existing ST–T abnormalities, LBBB or paced ventricular rhythm; transient ECG 
changes can be missed. Critically ill non-cardiac patients commonly have relative 
contra-indications to anticoagulants or cardiac catheterization (diagnostic and 
therapeutic) due to underlying medical conditions. Non-invasive evaluation in such 
patients is difficult to perform and gives limited information. Even after performing 
coronary angiogram in such patients, the decision to label patients as having ACS is 
difficult if there is no clear cut evidence of visible thrombus, slow flow or no flow 
phenomenon visualized on angiogram. These patients may also have coronary artery 
lesion which are stable and longstanding and not contributing to the present condition 
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(9). Finally, critically ill patients have multiple stressors and pro-coagulant conditions 
which can cause acute progression in severity of pre-existing coronary artery lesion 
(Type 1). There can also be concomitant cell damage from hypo-perfusion or hypoxia 
of non coronary etiology (Type 2) making simultaneous occurrence of both types of 
MI a possibility (8). In patients of Type 2 MI, the nature and severity of the illness 
inducing the cardiac biomarker elevation significantly alters the prognosis (8). 
                   Non-thrombotic troponin elevation (NTTE) is defined as troponin 
elevation in the existence of an additional definitive diagnosis which is known to be 
associated with rise in troponin levels, with lack of sufficient criteria for diagnosing 
acute coronary syndrome as per universal definition given by ESC/ACC/AHA and 
serial samples showing <20 % rise or fall from first value i.e. constantly elevated at 
the same level. NTTE will also be considered when normal epicardial coronaries are 
demonstrated on coronary angiography in patients with troponin elevation (10-12). 
                   In this study we have attempted to determine the significance of NTTE in 
relation to in- hospital and 30 day mortality, duration of hospitalization and its 
association with non cardiac conditions which are commonly associated with the 
NTTE in critically ill non-cardiac patients (CINCP).  The presence of such association 
would mean that patients with NTTE are at high risk which may benefit from 
intensive management. For clinical comparison we have also looked at cohort of 
patients in Coronary Care Unit (CCU)/ Chest Pain Unit (CPU) who presented with 
proven diagnosis of ST segment elevation myocardial infarction and Non ST elevation 
myocardial infarction (STEMI/ NSTEMI). 
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AIM:  
          Assessment of thrombotic and non-thrombotic troponin elevation 
 OBJECTIVES: 
1) To correlate troponin levels in critically ill non-cardiac patients (CINCP) and 
ACS patients with duration of hospitalization, in-hospital and 30 days mortality. 
2) To describe the range of troponin elevation, positive and negative predictors for non 
thrombotic troponin elevation (NTTE) in critically ill non-cardiac patients stratified 
according to APACHE II score. 
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REVIEW OF LITERATURE:                       
Troponins are proteins in thin filaments of sarcomere. It regulates the calcium-
triggered interaction of actin and myosin. Troponin T and I has cardiac form, which 
differs in amino acid sequence from muscle form. These proteins can be measured 
with monoclonal antibodies directed at epitopes present only in cardiac form. 
Troponin C has a common isoform in cardiac and smooth muscle hence not used 
clinically. Troponin is a marker of myonecrosis, and does not always imply coronary 
artery disease (1).             
 
FIGURE 2: TROPONINS LOCATIONS IN RESPECT TO ACTIN AND MYOSIN  
It has been documented that low level serum troponin elevation is chronically 
present in stable patients with diabetes mellitus, chronic renal failure, heart failure and 
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left ventricular hypertrophy (LVH) (8). In approximately 25% to 33% of athletes after 
the marathon, transient serum troponin elevations above the normal range can be 
detected, with no evident functional consequences (13-15). In critically ill non-cardiac 
patients assessing troponin elevations has became complicated  due to growing  list of 
causes of elevated troponin (6, 10, 16-19). Elevated serum troponin levels above 99th 
percentile can identify critically ill non-cardiac patients having a worse prognosis (20 
to 24).  In a study by Ammann et.al 72 % of troponin positive patients at autopsy or 
stress echocardiography did not showed any flow-limiting coronary artery stenosis 
(20). As compared to patients with Type I MI prognosis may be worse for critically ill 
non- cardiac patients with serum troponin elevation without any other evidence of MI 
(9, 11). 
Term ‘Secondary Unstable Angina’ has been used by the ACC/AHA guidelines 
for management of unstable angina (UA)/non-ST-elevation myocardial infarction 
(NSTEMI) to portray enzyme elevation precipitated by a condition which is extrinsic 
to the coronary arterial bed (25). In critically ill patients with troponin elevation, 
angina may not be present so terminologies such as ‘non-thrombotic troponin 
elevation’ (NTTE), ‘non-specific troponin elevation’, ‘troponin leak’, ‘concomitant 
myocardial injury’ and ‘troponin positive non-ACS’  ,have also been used (11). A 
meta-analysis was performed by Fleming et al. of the published trials of ACS patients 
without ST elevation and found that cTnI and cTnT provide similar information in for 
adverse events (death and myocardial infarction) (26).                                  
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CARDIAC TROPONIN T (27-39): 
Troponin T occurs in three diverse isoforms, each encoded by individual genes. 
It has been recognized in cardiac muscle, fast-twitch and slow-twitch skeletal muscle 
(27, 28). Cardiac troponin T has a sequence homology with skeletal muscle troponin T 
(sTnT), [56.6% homology- fast twitch sTnT and 56.6% homology- slow-twitch 
sTnT]. There is a differentiation of 125 amino acid residues between adult sTnT from 
fast-twitch skeletal muscle (fast sTnT) and cTnT and 120-residue differentiation 
between adult sTnT from slow-twitch skeletal muscle (slow sTnT) and cTnT (28). 
The majority of cTnT is found within the contractile apparatus (~10 mg/g tissue). 6% 
to 8% of cTnT occur as a free cytosolic component (29).   
Apoptosis, normal myocyte turnover, cellular release of proteolytic degradation 
products, increased cell wall permeability, and formation and release of membranous 
blebs are some of the proposed mechanisms of cardiac troponin release. In circulation 
the half-life of cTnT is considered to be 120 min, with the extended window of 
detection being due to incessant release of cTnT from the myofibrillar pool as within 
cell there is degradation of the contractile apparatus during necrosis (29). In patients 
with renal disease there is no evidence that adult TnT in skeletal muscle has any 
corresponding isoform which cross reacts with adult cTnT on use of the antibody pair 
specific to adult cTnT (31).  
The high sensitivity-cTnT assay uses fragment antigen binding (FAB) portions 
of two cTnT-specific mouse monoclonal antibodies (MAbs) directed against epitopes 
in the central region of human cTnT (32).  
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CARDIAC TROPONIN I (27 -39): 
A single isoform of human Cardiac troponin I (cTnI) occurs in cardiac muscle 
tissue. It has 209 amino acid residues and molecular weight in the order of 23–24 kDa. 
Three human cTnI isoforms have been described: one each is produced in cardiac 
muscle (cTnI), slow-twitch and fast-twitch skeletal muscles (slow sTnI and fast sTnI, 
respectively). Approximately 40% sequence overlap occurs between cTnI and slow 
sTnI and fairly less overlap for fast sTnI (27, 28). Antibodies preferred for cTnI assays 
can have cross-reaction with slow and fast skeletal isoforms of the troponin (27). 
Protein Kinase A can phosphorylate the two serine residues in cTnI molecule. 
Thus cTnI can coexist in the cell in different forms: dephosphorylated, 
monophosphorylated, and bisphosphorylated form. Interaction of cTnI with anti-TnI 
antibodies is modified by phosphorylation, as it changes conformation of proteins this 
modifies its interaction with other troponins. In circulation post-translationally 
modified TnI isoforms that are oxidized, reduced, or partially digested by proteases 
and phosphorylated isoforms appears in blood stream (33).  
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FIGURE 3: ROLE OF CALCIUM IN TROPONIN-TROPOMYOSIN COMPLEX -
MECHANISM OF ACTION  
The greater part of cTnI is found in the contractile apparatus (~ 4–6 mg/g 
tissue). 2% to 8% of cTnI occurs as a free cytosolic component. It is released by 
proteolytic degradation (34).   Cummins et al. described the first cTnI immunoassay in 
1987 (35). All known cTnI modifications circulating in the blood are recognized by 
monoclonal antibodies (MAbs) directed to selected epitopes of cTnI.  Multiple factors 
influence cTnI measurement like the posttranslational modifications [phosphorylation, 
proteolytic degradation] and complexing with other molecules [e.g., human antimouse 
antibodies or heterophile, TnC, heparin and cTnI-specific autoantibodies circulating in 
patients' blood] (36). It is recommended that in development of precise immunoassays 
combinations of >2 MAbs to be used. Antibodies used in the assay should identify 
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cTnI in complex with TnC as in human blood >95% of cTnI occurs as a binary cTnI–
TnC complex. Ideally, all circulating cardiac troponin forms should be recognized by 
antibodies used in assays on an equimolar basis (27). 
  Using commercial cTnT and cTnI assays which was measured on collected 
fractions, it was instituted that troponin is released into blood as free cTnT, a binary 
complex of cTnI-C, a ternary complex of cTnT-I-C and with no free cTnI within the 
confines of the analytical methodologies (27). 
TABLE 1: LIMIT OF DETECTIONS OF DIFFERENT TROPONIN 
GENERATIONS: 
TROPONIN  LIMIT OF DETECTION  
FIRST GENERATION  0.3 µg/L  
SECOND GENERATION  0.05 µg/L 
THIRD GENERATION  0.01-0.02 µg/L 
FOURTH GENERATION  0.03 ng/ml  
FIFTH GENERATION  3 ng/L 
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HIGH SENSITIVITY ASSAY (27, 40, 41): 
The term “high sensitivity” reflects the assay's characteristics and does not refer to a 
difference in the form of cardiac troponin being measured. 
• It was proposed that the assay would be labeled to be high sensitive if it met 
two essential criteria:  
1) The total imprecision (CV) at the 99th percentile value should be ≤10%.  
2) Measurable concentrations below the 99th percentile should be attainable with 
an assay at a concentration value above the assay's limit of detection for at least 
50% (and ideally >95%) of healthy individuals. 
 
• Concentrations for high sensitivity assays are expressed in nanograms per liter 
(ng/L) or picograms per milliliter (pg/ml). 
• Increase in assay sensitivity is achieved by:  
1) The sample volume was increased from 15 to 50 μL. 
2) The detection antibody ruthenium concentration was increased. 
3) Buffer optimization- lowers the background signal. 
• The calibration of assay is done against Escherichia coli cell culture produced 
recombinant human cTnT. 
• Fourth- generation assay cutoff of 30-ng/L equals to, 50 ng/L of the new high 
sensitivity assay.  
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• UNITS:  
1) Units are changed now the results are reported as whole numbers (old units 
x 1000).  
2) Current 0.03 limit is in ng/ml:  
3) 03 ng/ml       = 0.03 μg/l         = 30 ng/l          = 30 pg/ml 
4) Proposed change use ng/l or pg/ml when hsTnT adopted threshold for 
‘elevation’ (99th percentile) at 14 ng/L (0.014 ng/ml). 
 
TABLE 2: HIGH SENSITIVITY TROPONIN ASSAY (27) 
ROCHE 
ELECSYS 
(COMPANY 
ASSAY) 
CARDIAC TROPONIN CONCENTRATION 
AT: 
AMINO ACID 
RESIDUES OF 
EPITOPES 
RECOGNIZED 
BY CAPTURE © 
AND 
DETECTION (D) 
MAbs 
LIMIT OF 
DETECTION 
(ng/L) 
99% 
PERCENTILE 
(ng/L)- CV 
10% CV 
Concentration 
(ng/L) 
 5.0 14 (8%) 13 C:136-147;d125-
131 
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FIGURE 4: DIFFERENCES IN GENERATIONS OF TROPONIN ASSAY 
In meta-analysis of troponin T trials it was found to have PPV of 22.4% and 
NPV of 94% when sample timing was after 6 hours from onset of pain. Current assays 
for troponin estimation use population defined upper limit of 99th percentile for 
normality with coefficient of variation of less than 10% (25, 26, 42-45). Increased 
sensitivity can be achieved with sampling troponin every 6 to 8 hours (25).  
Myocardial necrosis leads to disruption of sarcolemmal membrane, 
disintegration of myofilament and subsequently macromolecules (serum cardiac 
markers) disperse into the cardiac interstitium and finally within microvasculature and 
lymphatic's. Initially the troponin from cytoplasmic pool is released. Cardiac troponin 
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levels increase to twenty to fifty times the upper reference limit (URL) in ACS 
patients with elevated CKMB levels. Troponin T is detected within 3 hours of 
myocardial ischemia, peaks in 12 to 24 hours and return to normal in 5 to 14 days. In 
patients with large reperfused myocardial infarction cTnT shows a characteristic 
biphasic time release pattern as compared with the monophasic release pattern that is 
visualized with cTnI. Idea regarding quality of micro vascular reperfusion may be 
given by the early appearing pool of troponin, whereas myocardial infarct size is 
reflected by the concentration of troponin T on 3rd or 4th day (29). 
UNIVERSAL DEFINITION OF MYOCARDIAL INFARCTION: 
Universal definition of myocardial infarction (ACS) as given by 
ESC/ACC/AHA includes typical rise and/or fall of biochemical markers of 
myocardial necrosis preferably cardiac troponins with at-least one value above 99th 
percentile of URL as major factor for diagnosis of ACS (5). The NACB recommends 
a 20% alteration from baseline value to be suggestive of and MI that is either 
evolving (delta positive) or resolving (delta negative).  
As given by Thygesan et.al (5) the term myocardial infarction should be used 
when there is evidence of myocardial necrosis in a clinical setting consistent with 
myocardial ischemia. Under these conditions, any 1 of the following criteria meets the 
diagnosis for MI- 
1. Detection of rise and/or fall of cardiac biomarkers (preferably Troponins) with ≥1 
value above the 99th percentile of the URL together with evidence of myocardial 
ischemia with ≥1 of the following: 
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a. Symptoms of ischemia 
b. ECG changes indicative of new ischemia (new ST-T changes or new LBBB) 
c. Development of pathological Q waves in the ECG 
 d. Imaging evidence of new loss of viable myocardium or new regional wall-motion 
abnormality 
e. Pathological findings of an acute MI. 
The  troponin value below 99th percentile has a very high negative predictive 
value for ACS. Type 2 MI as per ESC/ACC/AHA classification is due to supply 
demand mismatch without CAD.  Myocardial infarctions can be classified temporally 
from clinical and other features, as well as according to the pathological appearance, 
as evolving (<6 h), acute (6 h–7days), healing (7–28 days), and healed (29 days and 
beyond). Myocardial infarctions are usually classified by location of the infarct and by 
size: microscopic (focal necrosis), small [10% of the left ventricular (LV) 
myocardium], moderate (10–30% of the LV myocardium), and large (>30% of the LV 
myocardium) (9, 29).       
ISCHEMIC SYMPTOMS:  
A discomfort or pain (in a variety of combinations) in chest, jaw, left or right 
shoulder epigastric, wrist or arm occurring with exertion or at rest, persisting for at 
least 20 minutes, with radiation to the arm, hand, jaw, shoulder or back. It could be 
associated with diaphoresis, dyspnea, nausea, vomiting, or lightheadedness. The 
discomfort or pain is not exaggerated or decreased by pressure, movements and 
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position of body. Patient with ACS might not have typical symptoms. The atypical 
symptoms may comprise (but are not restricted to) of weakness, extreme fatigue, 
apprehension, mental confusion, anxiety, giddiness, syncope, nervousness and 
psychosis. Presentation with atypical symptoms is more common in females, old age, 
demented and diabetic patients. These symptoms are not precise for ACS and can also 
be caused by disorders associated with gastrointestinal, neurological, pulmonary, or 
musculoskeletal systems; thus, further assessment is needed to complement the 
clinical history.  
Types of Myocardial infarction (Joint ESC/ACCF/AHA/WHC Task force) (5): 
1) Type 1: Spontaneous myocardial infarction 
2) Type 2: MI secondary to an ischemic imbalance 
3) Type 3: MI resulting in death when biomarker values are unavailable 
4) Type 4a: MI related to PCI. (By convention, increases of biomarkers >3 ×99th-
percentile URL have been designated as defining PCI-related MI.) 
5) Type 4b: MI related to stent thrombosis (as documented by angiography or at 
autopsy.) 
6) Type 5: MI related to CABG (By convention, increases of biomarkers >5 
×99th-percentile URL  either new pathological Q waves or new LBBB, or 
angiographically documented new graft or native coronary artery occlusion, or 
imaging evidence of new loss of viable myocardium, have been designated as 
defining CABG-related MI) 
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ELECTROCARDIOGRAM (46): 
I) ECG manifestations of acute Myocardial Ischemia (in Absence of LVH and 
LBBB): 
1) New ST elevation at the J-point in 2 contiguous leads with the cutoff points: ≥0.2 
mV in men or ≥0.15 mV in women in leads V2 through V3and/or ≥0.1 mV in 
other leads. 
2) New horizontal or down sloping ST depression ≥0.05 mV in 2 contiguous leads; 
and/or T inversion ≥0.1 mV in 2 contiguous leads with prominent R wave or R/S 
ratio >1. 
II) ECG Changes Associated With Prior MI: 
1) Any Q wave in leads V2 through V3 ≥0.02 s or QS complex in leads V2 and 
V3. 
2) Q wave ≥0.03 s and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or 
V4 through V6 in any 2 leads of a contiguous lead grouping (I, aVL,V6; 
V4 through V6; II, III, and aVF) 
3) R wave ≥0.04 s in V1 through V2 and R/S ≥1 with a concordant positive T 
wave in the absence of a conduction defect. 
ECHOCARDIOGRAPHY IN ACUTE CORONARY SYNDROMES: (47-57) 
(ACC/AHA/ASE Guidelines, 2011 appropriate use criteria for echocardiography) 
 Regional wall motion abnormalities (RWMAs) –  
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1) It is defined as a localized decrease in the rate and amplitude of myocardial 
excursion with a blunted degree of myocardial thickening and associated 
local remodeling (47). 
2) RWMA is produced by ischemia which is visualized within seconds on 
echocardiography after coronary artery occlusion. In two series after 
transient coronary artery balloon occlusion within 12±5seconds and 19±8 
seconds respectively RWMAs was visualized (48, 49).  
3) If RWMA is due to acute ischemia the wall thickness and reflectivity will 
be preserved, but if RWMA is chronic, the wall will be akinetic and 
reflective (50). 
4) Ischemic RWMAs occurs prior to symptoms onset, chest pain occurring 
without RWMAs active myocardial ischemia is probably ruled out.  
5) RWMAs can occur due to prior infarction, prior surgery, focal or localized 
myocarditis, accessory pathway causing ventricular preexcitation, left 
bundle branch block, and cardiomyopathy.  
Study by Sabia et.al in 180 patients coming to emergency department with 
chest pain showed that echocardiography has a high sensitivity but a relatively lower 
specificity (51). Study results were as follows: In patients with ACS 27 of 29 had 
RWMA (93% sensitivity), RWMA suggested ACS in 31% patients and only 2.2% 
patients without RWMA were diagnosed as having NSTEMI on basis of cardiac 
enzymes (51). 
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               Myocardial ischemia is diagnosed if there is appearance of reversible 
RWMAs and reversible ECG changes (52). 
 
 
NON THROMBOTIC TROPONIN ELEVATION (NTTE) (10-12): 
NTTE is defined as 
1) Troponin elevation in the existence of an additional definitive diagnosis which 
is known to be associated with rise in troponin levels, with lack of sufficient 
criteria for diagnosing acute coronary syndrome as per universal definition 
given by ESC/ACC/AHA and serial samples showing <20 % rise or fall from 
first value i.e. constantly elevated at the same level.  
2) NTTE will also be considered when normal epicardial coronaries are 
demonstrated on coronary angiography in patients with troponin elevation. 
                     Non-thrombotic troponin levels elevation has been seen in many more 
conditions other than ACS. Troponins have compelling clinical values as it has 
superior potential in predicting the prognostic outcome of patients with elevated 
levels. 
CAUSES OF NONTHROMBOTIC TROPONIN ELEVATION (1, 58): 
• Chronic or acute renal dysfunction 
• Severe congestive heart failure—acute and chronic 
• Hypertensive crisis 
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• Tachy- or brady-arrhythmias 
• Pulmonary embolism, severe pulmonary hypertension 
• Inflammatory diseases, e.g., myocarditis 
• Acute neurological disease, including stroke or subarachnoid hemorrhage 
• Aortic dissection, aortic valve disease or hypertrophic cardiomyopathy 
• Cardiac contusion, ablation, pacing, cardioversion, or endomyocardial biopsy 
• Hypothyroidism 
• Apical ballooning syndrome (Takotsubo cardiomyopathy) 
• Infiltrative diseases, e.g., amyloidosis, hemochromatosis, sarcoidosis, scleroderma 
• Drug toxicity, e.g., Adriamycin, 5-fluorouracil, Herceptin, snake venoms 
• Burns, if affecting [≥30% of body surface area] 
• Rhabdomyolysis 
• Critically ill patients, especially with respiratory failure, or sepsis.  
• Vital exhaustion.  
• Transplant vasculopathy 
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TABLE 3: SERUM TROPONIN CONCENTRATION AND ASSOCIATED 
CONDITIONS AS PER SERUM LEVEL: 
Troponin 
concentration (µg/L) 
Clinical Conditions 
100 Large myocardial infarction 
10 Medium sized myocardial infarction, Severe myocarditis 
1 Small myocardial infarction, myocarditis, pulmonary 
embolism, shock. 
0.1 Micro myocardial infarction, pulmonary embolism, shock, 
acute heart failure, renal failure (acute/chronic), subarachnoid 
hemorrhage. 
0.01 Stable angina, chronic heart failure, left ventricular 
hypertrophy, subclinical heart disease,  
0.001 Healthy individual 
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FIGURE 5: TROPONIN LEVEL VARIATION AMONG DIFFERENT EVENTS 
In  acute pulmonary embolism, serum troponins perhaps rise due to acute right heart 
strain and overload. The troponin release as compared to unstable angina is of shorter 
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duration, and the peak level of troponin has prognostic value linked to the outcome 
(59, 60). 
            The reasons for troponin T and I elevations in patients with severe renal 
dysfunction are not yet convincingly explained but it cannot be linked to myocardial 
injury. Different analyses and investigators excluded re-expression of cardiac isoforms 
in skeletal muscles (61, 62). Due to impaired renal excretion normal low level 
troponins are amplified, also membrane integrity of myocytes is lost and there is 
constant outpouring from the free cytosolic troponin pool leading to abnormal 
troponin values (19). Significantly higher biological variation was seen in end-stage 
renal disease (ESRD) patients as compared to healthy reference individuals. In ESRD 
patient’s baseline serum cardiac troponin T concentration was more than 99th 
percentile of the healthy reference population and as the duration of haemodialysis 
increased the serum troponin level progressively increased. As compared to cTnI, 
Troponin T has high unbound cytosolic pool and molecular weight. This explains 
frequent elevation of cTnT as compared to cTnI in renal failure patients (19). When 
the cut off limit of 99th percentile was used in ESRD patients only 6% patients had 
increase in cTnI while 82% patients had an increase in cTnT (63). In GUSTO IV trial 
it was convincingly demonstrated that troponin T has predictive value for cardiac 
events in patients presenting with chest pain across all creatinine clearance levels (64). 
A study by Dierkes et al. in 102 ESRD patients found that cardiac troponin T is an 
important predictors of mortality (65). The prospective study by Apple et al 
documented 2- to 5-fold increase in one, two and three year all-cause mortality 
associated with levels of troponins. Independent of other variables, gradual rise in risk 
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occurs with rise in troponin T levels at various discriminator levels (63). After kidney 
transplantation the lower troponin levels was also associated with improved outcome 
(65). Studies suggest that if baseline serum troponin concentration is increased, 
additional rise in concentration higher than that at baseline occurs in acute ischemic 
injury. Consequently acute rise in serum troponin levels can be discriminated from 
more chronic persistent elevations when a rising pattern of results is seen (60, 66, and 
67). 
               Microembolization is a cause of troponin elevation. It induces inflammatory 
responses and might occur as a single or as multiple, repetitive events. When the 
fibrous cap of an atheroma ruptures, the lipid pool with or without added thrombus 
formation diffuses out of atheroma in the microcirculation causing spontaneous 
microembolization. Such phenomenons with progressive increase in thrombus burden 
are described as cyclic flow variations. The incidence of plaque rupture is more as 
compared to previous assumptions, i.e. in patient with normal structural heart having 
traffic accidents 9% had plaque rupture and similarly in diabetic and hypertensive 
patients 22% had event. Microembolisation is commonly found in patients with 
sudden death. In patients with normal epicardial coronaries on angiogram with ACS, 
ischemic and diabetic cardiomyopathy pathogenesis can be explained better by 
appreciation of microembolisation.  During PTCA rise in cTnI and cTnT and 
associated ST segment changes in ECG is caused due to microembolization (68, 69).              
                  Increases serum cTn levels are frequently seen amongst critically ill 
patients, e.g., patients with sepsis and it is co-related with prognosis. It is strongly 
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associated with the grade of left ventricular dysfunction and the requirement for 
inotropic support (70, 71). 
                Troponins are regularly elevated in histologically confirmed myocarditis, 
but in patients suspected of having myocarditis clinically 50% also shows rise in cTn 
levels. Abnormal troponins levels are more likely in the diffuse myocarditis than in 
focal disease. Troponins prognostic value in assessment of progression of left 
ventricular dysfunction in a patient of myocarditis has not yet been convincingly 
established (72, 73). 
                In study done by Mehta et al. patients on coronary angiogram having < 50% 
stenosis of any major coronary artery with elevated serum troponin levels (n = 83) 
were compared to patients with negative troponin levels. It was found that there was 
an increased incidence of re-infarction and death over a period of 2.5 years follow-up 
in the patients with elevated troponin and non-obstructive-epicardial CAD. The risk of 
death and MACCE at thirty days and one year was equal in the patients with elevated 
troponin levels and non-obstructive CAD with recognized cause as compared to 
patients with obstructive CAD (73).  
                 Sanchis et al. did a study on 1372 patients with non-ST-segment elevation 
acute chest pain indicated that the replacement of conventional cTn by hs-cTn patients 
increased pharmacological treatments for acute coronary syndrome and the number of 
coronary angiograms and revascularizations performed at the index episode, while the 
number of patients initially evaluated with non-invasive stress tests in the chest pain 
unit decreased. Despite of all clinical outcomes at 6 months were not changed (74). 
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                Javed et al. studied 701 patients with elevated troponin I found that among 
them only a minority of patients had ACS by the universal definition. The criteria of 
ACS were fulfilled by 216 patients (30.8% with increased TnI). Type 1 MI was 
diagnosed in 143 patients (20.4%), Type 2 MI was diagnosed in 64 patients (9.1%), 
while the criteria for ACS was not fulfilled by 461 patients (65.8%). ACS can be 
diagnosed with 70% sensitivity and specificity at Troponin I level of 0.28 ng/ml. Type 
1 AMI patients had increased chances of undergoing angiography and it was the most 
common AMI. Higher TnI values were seen with Type I AMI patients as compared to 
other patients. In the study illicit drug use was most common cause of Type 2 AMI 
(12).  
               Study by Ammann et.al showed that ICU patients with rise in serum cT 
levels above 99th percentile, >70% patients on stress echocardiography or at autopsy 
did not have flow-limiting epicardial coronary artery stenosis (20).                           
              S Hajsadegh et al. studied one hundred thirty five patients admitted to the 
medical ICU.  Patients mean age was 60.9 ± 21.5 years. Four blood samples were 
taken for troponin levels for evaluation. First sample was send within twenty four 
hours of ICU admission and then on the fourth, seventh and tenth days samples were 
send. Among the deceased and discharged patients the alteration in cTnT levels was 
not significantly different (p = 0.4). There was no significant trend visualized between 
changes in cTnT levels during ICU stay (power: 0.26). Worst survival was noted in 
patients whose cTnT levels were increased on the 1st and 7th days of ICU stay. This 
could be related with cardiac events on admission or at specific times during the stay 
in ICU (75). 
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             Relos RP et.al studied, 58 critically ill non-cardiac patients found that elevated 
troponin levels on admission were associated with a fourfold increased risk of 
mortality (76). 
              Vlad et.al studied in 2078 patients with ARDS, and found that high levels of 
cTnT on admission had an independent association with in-hospital, short and long-
term mortality (77). 
               Altmann et al. studied 38 patients with sepsis, septic shock or systemic 
inflammatory response syndrome (SIRS) without evidence of an ACS. Out of 38, 22 
(58%) patients were cTnI-positive. They analyzed coagulation parameters using 
rotational thrombelastometry and found no differences between cTnI-positive and -
negative patients with SIRS, severe sepsis, and septic shock. They concluded that 
pathophysiological mechanisms other than thrombus-associated myocardial damage 
might play a major role, including reversible myocardial membrane leakage and/or 
cytokine mediated apoptosis in these patients (78). 
                 Brekke et al. studied 396 COPD patients with acute exacerbation; elevated 
cTnT was associated significantly with increased all-cause mortality including in-
hospital mortality and after discharge (79). 
                  In general ICU critically ill non-cardiac patients increased serum troponin 
levels prevalence ranges from 15% to 70%, and similarly the prevalence is 31% to 
80% in critically ill patients with sepsis or septic shock. Estimated prevalence of non-
cardiac diagnoses in NTTE ranged from 16% to 55% (19, 80).  
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                Mcfalls et.al showed that in 21,668 patients with elevated serum troponin 
57.2% (12,400) patients had NTTE. Among NTTE patients CHF, Chronic CAD 
attributed mainly for NTTE. They found higher mortality in NTTE patients (22.8%) as 
compared to ACS patients (Odds Ratio=1.39; 95%CI: 1.30–1.49) (81). 
APACHE II SCORE ("Acute Physiology and Chronic Health Evaluation II"):  
              It is a severity-of-disease classification system given by Knaus et al. (82). It 
is applied to critically ill patients within 24 hours of admission to intensive care unit 
(ICU). Based on several measurements an integer score is computed from 0 to 71. 
Patients with higher APACHE II scores correspond to more severe disease and a 
higher risk of death. APACHE II score was designed to measure the severity of 
disease for adult patients admitted to intensive care units. APACHE II score is not 
validated for patient’s age ≤ 16.  
The point score is calculated from a patient's age and twelve routine physiological 
measurements as follows: 
1. (A-a)∆O2 or PaO2. (If FiO2 < 50% PaO2 is used; If FiO2 ≥ 50% A-a gradient 
is used ) 
2. Temperature (rectal) 
3. Mean arterial pressure 
4. Arterial pH  
5. Heart rate 
6. Respiratory rate 
7. Serum Sodium  
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8. Serum Potassium  
9. Serum Creatinine 
10. Hematocrit 
11. Total white blood cell count 
12. Glasgow coma scale 
            These were measured during the first 24 hours after admission, information 
about previous health status, and some information obtained at admission (such as 
age). The score is not recalculated during the stay; it is by definition an admission 
score. If a patient is discharged from the ICU and readmitted, a new APACHE II score 
is calculated. Patient’s prognosis (specifically, predicted mortality) was computed 
based on the patient's APACHE II score in combination with the principal diagnosis at 
admission. 
                             It has been seen that critically ill non-cardiac patients with increased 
troponins were having increased proinflammatory cytokine, TNF alpha, IL6, CRP and 
associated with increased mortality. It has been found that there is a negative 
correlation between troponin levels and LV systolic function (LVEF). Commonest 
cause of elevated troponin level in critically ill non-cardiac patients was ACS in 
around 50% to 60% of patients. Elevated cardiac troponin serum levels indicate 
myocardial injury but underlying mechanism can be multifactorial, signifying that to 
establish a diagnosis of ACS clinical evidence of coronary artery thrombosis is 
required (83). Troponins in ACS patients suggests that abnormal concentration of 
troponins almost always represents some irreversible myocardial injury, but in 
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critically ill non-cardiac patients the cardiac troponins might be released due to 
reversible myocardial ischemia without irreversible myocardial damage.  
                   Cardiac troponin levels correlate with higher risk of death and recurrent 
ischemic event in patients with ACS. In a medical ICU, critically ill non-cardiac 
patients with elevated serum levels of troponins exhibited a fourfold higher mortality 
rate (77). Similarly in critically ill non-cardiac patients in a surgical ICU, moderate 
elevations in troponin I were associated with increased duration of ICU and hospital 
stay and higher mortality rates (84, 85). Mortality in patient with non-thrombotic 
troponin elevation is many folds higher as compared to patient with ACS (86). 
Various studies has show that patients with a diagnosis of myocardial infarction 
benefit from thrombolytic therapy, coronary revascularization, and use of 
anticoagulants, antiplatelet agents, β-blockers, statins, and angiotensin-converting 
enzyme inhibitors. However patients with non-thrombotic troponin elevations may not 
respond favorably to antithrombotic agents and the impact of these therapies on 
outcomes in ICU patients with myocardial infarction is unknown. Understanding the 
etiology of troponin elevation in critically ill non-cardiac patients will help to better 
target appropriate therapies for ACS in these patients. This study will show 
significance of thrombotic and non-thrombotic troponin elevation, its clinical 
importance in early risk stratification and prognostication. 
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MATERIAL AND METHODS: 
                       The study was conducted in department of Cardiology and Medicine-
division of Critical Care, Christian Medical College Vellore. The study subjects were 
selected from 100 critically ill non-cardiac patients (APACHE II score ≥12) with 
troponin elevation more than 99th percentile of the Upper Reference Limit (URL) i.e. 
≥14 ng/L or pg/ml and 100 patients with ACS admitted in MICU/HDU and 
CCU/CPU respectively in our hospital. The study was conducted for 18 months from 
August 2013 to December 2014 in the department of Cardiology and Medicine-
division of Critical Care.  
TYPE OF STUDY: 
Observational cross sectional study. 
INCLUSION CRITERIA: 
1) Age ≥ 18 years 
2) Patients of ACS admitted in CCU/CPU 
3) Critically ill non-cardiac patients (APACHE II score ≥ 12) with elevated troponin 
levels (≥ 14 pg/ml or ng/L) admitted in MICU/MHDU. 
EXCLUSION CRITERIA: 
1) Consent not given by patient/relatives 
2) Out of hospital cardiac arrest who died within 48 hours of hospitalization 
3) Age < 18 years  
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METHODS: 
1) Serum troponin measurement within 24 hours of admission (Baseline sample).  
2) Second set of troponin and CKMB sample was send within 24 hours (preferably 
within 6 to 8 hours) of baseline sample (Second sample) 
3) APACHE II score was calculated with-in 24 hours of admission in MICU/ MHDU 
based on worst value up-to that point. 
            We collected details of the patients based on their clinical presentation, in 
which we looked for constitutional symptoms, risk factors for coronary artery disease, 
ECG, Echocardiography -LV systolic function, RWMA & renal parameters on the 
basis of thorough history taking and clinical examination. Details of patients were 
entered in a detailed pro forma. If patient was not able to give history it was assessed 
from relatives of the patient. 
                 Troponin baseline sample was send by the respective Unit looking after the 
patient on clinical suspicion of ACS and patients with elevated troponin level above 
99th percentile of URL for normal population (≥14 pg/ml) within 24 hours of 
admission were included in the study. Second set of troponin and CKMB samples 
were send within 24 hours (preferably within 6 to 8 hours) of baseline sample.  
              All patients were treated as per standard protocols and guidelines. Statistical 
analysis was performed to correlate troponin levels in critically ill non-cardiac 
patients and ACS patients with duration of hospitalization, in-hospital and 30 days 
mortality. 
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                We studied the demographic profile of these patients. We looked for 
predictors (age, sex, diabetes mellitus, hypertension, past history of coronary artery 
disease, renal function, troponin levels) which are positively and negatively 
associated with NTTE in critically ill non-cardiac patient with elevated troponin 
levels.        
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DETAILED DIAGRAMMATIC ALGORITHM OF THE STUDY: 
 
      Observational       Study 
                          In 
      Department of Cardiology  
                        and  
      Medicine-Critical care division 
   
 
 
 
 
 
 
 
 
 
     
 
 
  
 
 
Inclusion Criteria 
1)Age ≥18  
2)Patients of ACS admitted in CCU/CPU 
3)Critically ill non-cardiac patients 
    (APACHE II score >12) with elevated  
     troponin levels  (≥ 14 pg/ml) admitted  
     in MICU/MHDU 
Methods 
1) Serum troponin measurement within 24 hours of 
admission 
2) Second set of troponin and CKMB sample within 24 
hours of first sample 
3) APACHE II score calculated with-in 24 hours of 
admission in MICU/ MHDU based on worst value up-to 
that point 
 
Exclusion Criteria 
1) Consent not given by 
patient/relatives 
2) Out of hospital   cardiac 
arrest who died within 48 
hours of hospitalization 
3) Age < 18 years 
Objectives 
To correlate troponin levels in critically ill 
non- cardiac patients and ACS patients with: 
1) Duration of hospitalization,  
2) In-hospital and 30 days mortality. 
3) To identify predictors –Positive  
 or negative for NTTE 
4) Describe the range of troponin elevation in 
 Critically ill non-cardiac patients in MICU 
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UNIVERSAL DEFINITION OF MYOCARDIAL INFARCTION: 
                     Universal definition of myocardial infarction (ACS) as given by 
ESC/ACC/AHA includes typical rise and/or fall of biochemical markers of 
myocardial necrosis preferably cardiac troponins with at-least one value above 99th 
percentile of URL as major factor for diagnosis of ACS. The NACB recommends a 
20% change from baseline value to be suggestive of and MI that is either evolving 
(delta positive) or resolving (delta negative).  
                  As given by Thygesan et.al (5) the term myocardial infarction should be 
used when there is evidence of myocardial necrosis in a clinical setting consistent with 
myocardial ischemia. Under these conditions, any 1 of the following criteria meets the 
diagnosis for MI 
1. Detection of rise and/or fall of cardiac biomarkers (preferably Tn) with ≥1 value 
above the 99th percentile of the URL together with evidence of myocardial ischemia 
with ≥1 of the following: 
a. Symptoms of ischemia 
b. ECG changes indicative of new ischemia (new ST-T changes or new LBBB) 
c. Development of pathological Q waves in the ECG 
 d. Imaging evidence of new loss of viable myocardium or new regional wall-motion 
abnormality 
e. Pathological findings of an acute MI. 
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PREDICTORS OF ACS:  
Following were used as predictors of ACS in the study  
1) Chest pain  
2) ECG changes suggestive of ACS 
3) Echocardiogram changes suggestive of ACS  
4)  ≥ 20% troponin level delta change from first to second troponin serum sample  
• When ≥ 3 predictors are present the patient was diagnosed as having ACS. 
 ISHCHEMIC SYMPTOMS (5, 25, 87):  
1) A discomfort or pain (in a variety of combinations) in chest, jaw, left or right 
shoulder epigastric, wrist or arm occurring with exertion or at rest, persisting 
for at least 20 minutes, with radiation to the arm, hand, jaw, shoulder or back. 
It could be associated with diaphoresis, dyspnea, nausea, vomiting, or 
lightheadedness. 
2)  The discomfort or pain is not exaggerated or decreased by pressure, 
movements and position of body.  
3) Patient with ACS might not have typical symptoms. The atypical symptoms 
may comprise (but are not restricted to) of weakness, extreme fatigue, 
apprehension, mental confusion, anxiety, giddiness, syncope, nervousness and 
psychosis. 
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TYPICAL CHEST PAIN (87):  
In 1978 Heberden et.al has given initial definition of typical chest pain that can be 
attributed to ischemia:  
1) A painful sensation or discomfort in the chest accompanied by a strangling 
sensation, anxiety and occasional radiation of pain to the left arm. 
2) Chest pain increasing with exertion and/ or emotional stress.  
3) Chest pain relieving with rest and/or nitroglycerine.  
When all three criteria’s were fulfilled chest pain was labeled as typical chest 
pain. Symptoms out of these definitions were labeled as atypical.  
                                
ELECTROCARDIOGRAM (46): 
I) ECG manifestations of acute Myocardial Ischemia (in Absence of LVH and 
LBBB): 
1) New ST elevation at the J-point in 2 contiguous leads with the cutoff points: ≥0.2 
mV in men or ≥0.15 mV in women in leads V2 through V3and/or ≥0.1 mV in 
other leads. 
2) New horizontal or down sloping ST depression ≥0.05 mV in 2 contiguous leads; 
and/or T inversion ≥0.1 mV in 2 contiguous leads with prominent R wave or R/S 
ratio >1. 
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II) ECG Changes Associated With Prior MI: 
1) Any Q wave in leads V2 through V3 ≥0.02 s or QS complex in leads V2 and V3. 
2) Q wave ≥0.03 s and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or 
V4 through V6 in any 2 leads of a contiguous lead grouping (I, aVL,V6; 
V4 through V6; II, III, and aVF)  
3) R wave ≥0.04 s in V1 through V2 and R/S ≥1 with a concordant positive T wave 
in the absence of a conduction defect. 
 
ECHOCARDIOGRAPHY IN ACUTE CORONARY SYNDROMES (47-57) 
Regional wall motion abnormality (RWMA): 
1) It is defined as a localized decrease in the rate and amplitude of myocardial 
excursion with a blunted degree of myocardial thickening and associated local 
remodeling.  
2) Detection of new RWMAs with preserved wall thickening and reflectivity will 
support for diagnosing ACS in association with other ACC/AHA criteria. 
 
NON THROMBOTIC TROPONIN ELEVATION (NTTE) (10-12): 
NTTE is defined as 
1) Troponin elevation in the existence of an additional definitive diagnosis which 
is known to be associated with rise in troponin levels, with lack of sufficient 
criteria for diagnosing acute coronary syndrome as per universal definition 
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given by ESC/ACC/AHA and serial samples showing <20 % rise or fall from 
first value i.e. constantly elevated at the same level.  
2) NTTE will also be considered when normal epicardial coronaries are 
demonstrated on coronary angiography in patients with troponin elevation. 
 
ANAEMIA (88, 89): 
In critically ill patients significant anemia was defined as a hemoglobin concentration 
<9 gm/dl.  
ACUTE KIDNEY INJURY (KDIGO):  
 It was defined by any of the following (90): 
1) Within 48 hours the serum creatinine increased by ≥0.3 mg/dl (≥26.5 µmol/L); 
or 
2) Increase in serum creatinine by ≥1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 days; or 
3) Urine output < 0.5 ml/ kg per hour for 6 hours 
 
TROPONIN T ASSAY (27, 40, 41): 
Roche Elecsys high sensitivity troponin T assay was used for the study. The limit of 
detection of the assay was 5 ng/L, 10% co-efficient of variation was 13 ng/L and 99% 
percentile value was 14 ng/lt.  
1)  It works on Sandwich principle.  
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2) Duration required for completion of assay is 18 minutes.  
3) Sample is incubated twice.  
4) During 1st incubation 50 μL of sample is taken which forms a sandwich 
complex with a ruthenium labeled and biotinylated monoclonal cTnT specific 
antibody respectively 
5) During 2nd incubation streptavidin-coated micro particles are added to 
sandwich complex. With interaction of biotin and streptavidin it is then bound 
to the solid phase.  
6) This reaction mixture is aspirated into the measuring cell where the micro 
particles are magnetically captured onto the surface of the electrode.  
7) Chemiluminescent emission is induced after application of a voltage to the 
electrode which is measured by a photomultiplier.  
8) Calibration curve was used to determine the result. Curve was instrument-
specifically generated by 2-point calibration and a master curve (5-point 
calibration) provided via the reagent barcode. 
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STATISTICAL ANALYSIS: 
The data for all groups will be expressed as mean ± SD. Descriptive analysis was used 
to find out number and percentages. Categorical values were reported as proportion 
and percentages and it was compared using Chi-Square test.  For continuous variables, 
mean with standard deviation was used and it was compared using independent 
sample t-test if normal and Mann-Whitney U test if not normal in Univariate analysis. 
The variables which were significant at Univariate analysis were taken for 
Multivariate analysis. Survival analysis was used to find association between in-
hospital mortality and troponin levels in thrombotic ACS group and NTTE group. To 
find the cut-off levels of Apache score, ROC curve was used. The analysis was 
performed by using SPSS 16 version. 
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RESULTS: 
TABLE 1: AGE OF PATIENTS AMOUNG MICU AND CCU GROUPS AND 
SUBGROUPS 
GROUPS SUBGROUPS SUBGROUPS 
AGE (YEARS) 
MEAN ± SD 
CCU AND MICU GROUPS 
AGE (YEARS)  
MEAN ± SD  
MICU (N=100) NTTE (58) 53.16 ± 18.321 55.7 ± 16.864 
MICU-ACS (42) 59.21 ± 14.079 
CCU (N=100) CCU- NSTEMI (N=44) 63.59 ± 10.957 57.75 ± 11.673 
CCU- STEMI (N=56) 53.16 ± 10.133 
 
FIGURE 1: AGE OF PATIENTS AMOUNG MICU AND CCU SUBGROUPS 
 
• Table and bar diagram showing that age of patients (Mean and SD) in CCU and 
MICU groups included in study were comparable. 
• CCU- NSTEMI cases were significantly older than STEMI cases (63.59 ± 10.957 
vs. 53.16 ± 10.133, p value 0.000). 
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TABLE 2: SEX DISTRIBUTION IN CCU GROUP- STEMI VS. NSTEMI 
SEX DISTRIBUTION IN CCU GROUP- STEMI VS. NSTEMI 
CCU 
TOTAL 
P VALUE 
SEX STEMI NSTEMI 
FEMALE 5(26.3%) 14(73.7%) 19 0.05 
MALE 51 (63%) 30 (37%) 81 
TOTAL 56 44 100 
 
FIGURE 2: BAR DIAGRAM SHOWING SEX DISTRIBUTION IN CCU GROUP- STEMI 
VS. NSTEMI 
 
Table and bar diagram revealing that male sex was statistically significantly associated 
with ACS in CCU group (P value 0.05).  
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TABLE 3: MICU GROUP (THROMBOTIC AND NTTE) DEMOGRAPHICS 
TABLE 3A: TABLE SHOWING SEX DISTRIBUTION IN NTTE AND THROMBOTIC 
ACS PATIENTS 
SEX THROMBOTIC -
ACS 
NTTE TOTAL P VALUE 
MALE 23 28 51 0.522 
FEMALE 19 30 49 
TOTAL 42 58 100 
 
FIGURE 3A: BAR DIAGRAM COMPARING SEX DISTRIBUTION IN NTTE AND 
THROMBOTIC ACS PATIENTS 
 
Table and bar diagram showing that sex was not significantly associated with troponin 
elevation in NTTE patients (LR-0.411, p value 0.522). 
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TABLE 4: MICU GROUP PATIENTS COMORBIDITIES: 
TABLE 4A: TABLE SHOWING INCIDENCE OF HYPERTENSION IN NTTE AND 
THROMBOTIC ACS PATIENTS 
 
FIGURE 4A: BAR DIAGRAM COMPARING INCIDENCE OF HYPERTENSION IN 
NTTE AND THROMBOTIC ACS PATIENTS 
 
• Table and bar diagram showing hypertension incidence among thrombotic ACS 
and NTTE patients.  
• Hypertension was non-significantly associated with troponin elevation in NTTE 
patients (LR- 1.712; p value 0.191; Odds ratio-0.586; 95% CI- 0.262 -1.310%) 
0
5
10
15
20
25
30
35
THROMBOTIC -ACS(N=42) NTTE (N=58)
YES
NO
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ACS 
NTTE TOTAL P 
Value 
ODDS 
RATIO 
95% 
CONFIDENCE 
INTERVAL 
LOWER UPPER 
YES 24 25 49 0.191 0.586 0.262 1.310 
NO 19 32 51 
TOTAL 43 57 100 
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TABLE 4B: TABLE COMPARING INCIDENCE OF DIABETES MELLITUS IN NTTE 
AND THROMBOTIC ACS PATIENTS AND ITS SIGNIFICANCE 
DM II THROMBOTIC 
-ACS 
NTTE TOTAL P 
VALUE 
ODDS 
RATIO 
95% CONFIDENCE 
INTERVAL 
YES 21 27 48 0.416 0.812 LOWER UPPER 
NO 23 29 54 0.367 1.801 
TOTAL 44 56 100 
 
FIGURE 4B: BAR DIAGRAM COMPARING INCIDENCE OF DIABETES MELLITUS 
IN NTTE AND THROMBOTIC ACS PATIENTS 
 
• Table and bar diagram comparing incidence of diabetes mellitus type II among 
thrombotic ACS and NTTE patients.  
• DM II was non-significantly associated with troponin elevation in NTTE patients 
(Likelihood Ratio-2.485; p value 0.416; Odds ratio-0.812; 95% confidence 
interval- 0.367 – 1.801%) 
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TABLE 4C: TABLE SHOWING INCIDENCE OF PAST HISTORY OF CAD IN NTTE 
AND THROMBOTIC ACS PATIENTS 
PAST 
H/O 
CAD/CVA 
THROMBOTIC 
-ACS 
NTTE TOTAL P 
VALUE 
ODDS 
RATIO 
95% 
CONFIDENCE 
INTERVAL 
YES 9 9 18 0.451 0.673 LOWER UPPER 
NO 33 49 82 0.242 1.875 
TOTAL 42 58 100 
 
FIGURE 4C: BAR DIAGRAM COMPARING INCIDENCE OF PAST HISTORY OF 
CAD IN NTTE AND THROMBOTIC ACS PATIENTS 
 
• Table and bar diagram comparing incidence of past history of CAD among 
thrombotic ACS and NTTE patient.  
• It was non-significantly associated with troponin elevation in NTTE patients 
(LR-4.382, p value 0.451; Odds ratio-0.673; 95% CI - 0.242 -1.875%) 
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TABLE 4D: TABLE SHOWING INCIDENCE OF RENAL FAILURE IN NTTE AND 
THROMBOTIC ACS PATIENTS 
RENAL 
FAILURE 
THROMBOTIC 
-ACS 
NTTE TOTAL P 
VALUE 
ODDS 
RATIO 
95% 
CONFIDENCE 
INTERVAL 
YES 23 40 63 0.147 1.836 LOWER UPPER 
NO 19 18 37 0.805 4.184 
TOTAL 42 58 100 
FIGURE 4D: BAR DIAGRAM COMPARING INCIDENCE OF RENAL FAILURE IN 
NTTE AND THROMBOTIC ACS PATIENTS 
 
• Table and bar diagram comparing incidence of renal failure among thrombotic 
ACS and NTTE patients. 
• It was significantly associated with troponin elevation in NTTE patients in 
comparison to ACS patients but the association was not statistically significant 
(LR-0.037; p value 0.147; Odds ratio-1.836; 95%CI - 0.805 -4.184%). 
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TABLE 5: TABLE COMPARING INCIDENCE AND PERCENTAGES OF DIFFERENT 
COMORBIDITIES AMONG PATIENT OF CCU AND MICU GROUPS 
COMORBIDITIES CCU (N=100) MICU (N=100) 
CHEST PAIN 88 (88%) 11* (11%) 
TYPICAL CHEST PAIN 60 (68%) 5 (45%) 
DIABETES MELLITUS 46 (46%) 48 (48%) 
HYPERTENSION 50 (50%) 49 (49%) 
SMOKER 43 (43%) 23 (23%) 
HYPOTHYROIDISM 5 (5%) 3 (3%) 
DYSLIPIDEMIA 81 (81%) 35 (35%) 
PAST HISTORY OF 
CAD/CVA 
21 (21%) 18 (18%) 
RENAL FAILURE 15 (15%) 63 (63%) 
INTUBATED 2 (2%) 73 (73%) 
 
•  73 Patients in MICU were intubated and symptoms cannot be assessed. 
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TABLE 6: COMORBIDITIES ASSOCIATED WITH MICU GROUP (THROMBOTIC 
ACS AND NTTE) PATIENTS AND THEIR SIGNIFICANCE 
COMORBIDITIES THROMBOTIC -
ACS 
NTTE P VALUE 
HYPERTENSION 24 25 0.191 
DIABETES MELLITUS 21 25 0.416 
SMOKER 10 13 0.870 
HYPOTHYROIDISM 2 1 0.379 
DYSLIPIDEMIA 19 16 0.068 
PAST HISTORY OF CAD 9 9 0.451 
RENAL FAILURE 26 37 0.147 
INTUBATED 30 43 0.450 
 
FIGURE 5: BAR DIAGRAM COMPARING INCIDENCE OF DIFFERENT 
COMORBIDITIES IN NTTE AND THROMBOTIC ACS PATIENTS 
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TABLE 7: DIAGNOSIS ASSOCIATED WITH ELEVATED TROPONIN IN 
CRITICALLY ILL MICU PATIENT SUBSET: 
ETIOLOGICAL DIAGNOSIS INCIDENCE 
(N=100) 
NTTE  
(N=58) 
THROMBOTIC 
ACS (N=42) 
SEPSIS 70  45 (77.59%) 25(59.52%) 
ARF/ACUTE ON CKD 63 40 (68.97%) 23 (54.76%) 
ANAEMIA 43 25(43.10%) 18 (42.87%) 
SHOCK 18 18(31.03%) 0 
PNEUMONIA 15 15(25.86%) 0 
ARDS 12 12(20.69%) 0 
MYOCARDITIS 7 7(12.07%) 0 
CHF 6 6(10.34%) 0 
TACHYARRHYTHMIA 4 4(6.9%) 0 
CPR 4 4(6.9%) 0 
COPD 2 2(3.49%) 0 
BRADYARRHYTHMIA 1 1(1.72%) 0 
RHD 1 1(1.72%) 0 
DIABETIC KETOACIDOSIS 1 1(1.72%) 0 
AIDP 1 1(1.72%) 0 
CVA 1 1(1.72%) 0 
GTCS 1 1(1.72%) 0 
SNAKE BITE 1 1(1.72%) 0 
 
55 
 
FIGURE 6A: BAR DIAGRAM SHOWING DIAGNOSIS ASSOCIATED WITH 
ELEVATED TROPONIN IN CRITICALLY ILL MICU PATIENT SUBSET  
 
 
FIGURE 6B: PIE DIAGRAM SHOWING DIAGNOSIS ASSOCIATED WITH 
ELEVATED TROPONIN IN CRITICALLY ILL MICU PATIENT SUBSET 
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TABLE 8: COMPARISION OF CARDIAC BIOMARKERS AMONG FOUR 
SUBGROUPS 
COMPARISION OF CARDIAC BIOMARKERS AMONG SUBGROUPS 
SUBGROUPS CKMB1 CKMB2 TROP T1 TROP T2 
CCU-STEMI (N=56) 77.16 ± 
136.59 
162.80 ± 
157.87 
1294.41 ± 
2418.77 
5162.20 ± 
3635.84 
CCU-NSTEMI (N= 44) 
 
21.02 ± 
45.88 
34.57 ± 43.23 347.17 ± 566.90 983.47 ± 1922.34 
MICU-ACS  (N= 42) 
 
9.88 ± 
11.42 
30.36 ± 64.63 373.04 ± 1124.51 743.30 ± 1303.90 
NTTE (N=58) 
 
8.19 ± 9.16 7.5102 ± 6.39 289.16 ± 1062.26 258.62 ± 891.41 
 
FIGURE 7A: BAR DIAGRAM SHOWING COMPARISION OF TROPONIN T LEVELS 
AMONG ALL FOUR SUBGROUPS OF STUDY 
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FIGURE 7B: LINE DIAGRAM SHOWING COMPARISION OF TROPONIN T LEVELS 
AMONG ALL FOUR SUBGROUPS OF STUDY 
 
 
• Table and bar diagram showing variation of cardiac biomarkers levels among all 
four subgroups included in the study. 
• A range of troponin elevation is seen --- CCU-STEMI > CCU-NSTEMI > MICU-
ACS > MICU-NTTE. 
• First Sample- Baseline sample send within first 24 hours of patient’s admission 
to CCU/ CPU/ MICU/ MHDU. 
• Second sample- Blood sample send within 24 hours of first sample (6 to 8 hours 
on an average). 
• Troponin level was measured in ng/L or pg/ml and CKMB level was measured in 
ng/ml.  
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TABLE 9: COMPARISION OF CARDIAC BIOMARKERS LEVELS IN CCU-NSTEMI 
PATIENTS WITH MICU-ACS PATIENTS 
COMPARISION OF CARDIAC 
BIOMARKERS LEVELS IN CCU-NSTEMI 
PATIENTS WITH MICU-ACS PATIENTS 
P value 95% Confidence 
Interval of the 
Difference 
 
group N 
Mean ±  Std. 
Deviation 
Std. 
Error 
Mean 
Equal 
variances 
assumed 
Equal 
variances 
not 
assumed 
Lower Upper 
CKMB1 CCU-
NSTEMI 44 
21.02 
± 45.88 
6.92 
                        
0.130 
                 
              
0.125 
-3.31 25.64 
MICU-
ACS 42 
9.88 
± 11.42 
1.76 
-3.21    25.49 
CKMB2 CCU-
NSTEMI 44 
34.57 
± 43.23 
6.52 
0.722 0.724 
-19.26 27.69 
MICU-
ACS 42 
30.36 
± 64.63 
9.97 -19.54 27.97 
TROPT1 CCU-
NSTEMI 44 
347.17 
± 566.90 
85.46 
                  
0.892 
                   
                      
0.894 -405.17 353.42 
MICU-
ACS 42 
373.04 
± 1124.51 
173.52 -412.78 361.04 
TROPT2 CCU-
NSTEMI 44 
983.47 
± 1922.34 
289.81 
                  
0.502 
        
  
0.498 -467.56 947.87 
MICU-
ACS 42 
743.31 
± 1303.90 
201.20 -462.51 942.83 
 
 
59 
 
FIGURE 8A: LINE DIAGRAM COMPARING CARDIAC BIOMARKERS LEVELS IN 
CCU-NSTEMI PATIENTS WITH MICU-ACS PATIENTS 
 
FIGURE 8B: BAR DIAGRAM COMPARING CARDIAC BIOMARKERS LEVELS IN 
CCU-NSTEMI PATIENTS WITH MICU-ACS PATIENTS 
  
• Serum troponin levels in NSTEMI patient in CCU (Trop T 1st and 2nd sample 
was 347.17 ± 566.90 and 983.47 ± 1922.34 respectively) and ACS patients in 
MICU (Trop T 1st and 2nd sample was 373.04 ± 1124.51 and 743.31 ± 1303.90 
respectively) were comparable.  
• ‘p value’ for Troponin T 1st and 2nd sample is 0.892 and 0.502 respectively. 
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TABLE 10: COMPARISION OF CARDIAC BIOMARKERS LEVELS IN MICU-NTTE 
PATIENTS WITH MICU-ACS PATIENTS 
COMPARISION OF MICU-NTTE PATIENTS WITH MICU-ACS PATIENTS 
GROUP CKMB1 CKMB2 TROPT1 TROPT2 
MICU-ACS 
(N=42) 
Mean ±Std. 
Deviation 
9.88 ±  
11.42 
30.36 
± 64.63 
373.04 
± 1124.51 
743.31 
± 1303.90 
NTTE 
(N=58) 
Mean  ± 
Std. Deviation 
8.19 
±  9.16 
7.51 
±  6.39 
289.16 
±  1062.26 
258.62 
±  891.41 
P VALUE 0.675 0.000 0.058 0.000 
 
FIGURE 9A: BAR DIAGRAM COMPARING CARDIAC BIOMARKERS LEVELS IN 
MICU-NTTE PATIENTS WITH MICU-ACS PATIENTS 
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FIGURE 9B: LINE DIAGRAM COMPARING CARDIAC BIOMARKERS LEVELS IN 
MICU-NTTE PATIENTS WITH MICU-ACS PATIENTS 
 
• Troponin T level in ACS patients (Trop T 1st and 2nd sample was 373.04 ± 
1124.51 and 743.31 ± 1303.90 respectively) was significantly higher than troponin 
T level in NTTE patients (Trop T 1st and 2nd sample was 289.16 ± 1062.26 and 
258.62 ± 891.41 respectively) 
•  ‘p value’ for Troponin T 1st and 2nd sample is 0.05 and 0.000 respectively for the 
association.  
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TABLE 11: CO-RELATION OF TROPONIN T 1ST AND 2ND SAMPLE LEVEL WITH 
DURATION OF HOSPITALISATION IN MICU PATIENTS 
DURATION OF 
HOSPITALISATION 
N PEARSON 
CORRELATION 
SIGNIFICANCE 
TROP T 1 100 -0.068 0.501 
TROP T  2 100 -0.072 0.479 
 
• Table presenting co-relation and significance of Troponin T 1st and 2nd sample 
levels with duration of hospitalization.  
• Troponin T 1st and 2nd sample level were negatively co-related with duration of 
hospitalization, Pearson co-relation coefficient for Trop T 1st and 2nd sample was 
-0.068 and -0.072 respectively.  
• It was not a significant co-relation (p value for Trop T 1st and 2nd sample 0.501 
and 0.479 respectively).   
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TABLE 12: ASSOCIATION OF TROPONIN T BASELINE AND SECOND SAMPLE 
LEVELS WITH IN-HOSPITAL MORTALITY IN MICU PATIENTS 
 In-hospital 
mortality N Mean ± Std. Deviation Std. Error Mean 
P value 
TROPT1 Mortality 29 699.03 ± 1953.03 362.67 0.026 
Alive 71 171.36 ±  233.05 27.67 
TROPT2 Mortality 29 681.96 ±  1782.04 330.92 0.205 
Alive 71 372.42 ±  652.81 77.47 
 
FIGURE 10: LINE DIAGRAM SHOWING ASSOCIATION OF TROPONIN T 1st AND 
2nd SAMPLE LEVEL WITH IN-HOSPITAL MORTALITY IN MICU PATIENTS 
 
•  Baseline troponin levels were significantly associated with in-hospital mortality 
(p value 0.026) while 2nd sample troponin levels were not significantly associated 
with in-hospital mortality (p value 0.205). 
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TABLE 13: CO-RELATION OF TROPONIN BASELINE AND SECOND SAMPLE 
LEVELS WITH OUTCOME (MORTALITY, RE-HOSPITALISATION) ≤ 30 DAYS 
AFTER DISCHARGE IN MICU PATIENTS 
 
N 
Mean 
± Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
P 
VALUE 
Lower 
Bound 
Upper 
Bound 
TROPT 
1ST 
SAMPLE 
MORTALITY 
9 
148.82 
± 246.54 
82.18 40.69 338.32 
0.157 
REHOSPITALISATION 
5 
161.60 
± 290.18 
129.77 198.71 521.90 
NONE 
57 
169.51 
±  228.38 
30.25 108.92 230.11 
TROP T 
2ND 
SAMPLE 
MORTALITY 
9 
438.40 
± 964.39 
321.46 302.90 1179.69 
0.564 
REHOSPITALISATION 
5 
175.50 
± 324.68 
145.20 227.65 578.65 
NONE 
57 
370.43 
± 624.05 
82.66 204.85 536.02 
 
Table showing troponin T baseline and second sample levels were not significantly 
associated with mortality or re-hospitalization ≤ 30 days after discharge (p value = 0.157 
and 0.564).  
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TABLE 14: CO-RELATION OF SERUM TROPONIN LEVELS WITH OUTCOME (IN-
HOSPITAL MORTALITY, MORTALITY ≤ 30 DAYS AFTER DISCHARGE, RE-
HOSPITALISATION) IN CCU PATIENTS  
SAMPLE OUTCOME N MEAN ±  STD. 
DEVIATION 
TROP T 1ST 
(BASELINE)SAMPLE 
NO EVENTS 94 868.34 ± 1943.938 
INHOSPITAL 
MORTALITY 
1 2580.00 
 
MORTALITY ≤ 30 DAYS 
AFTER DISCHARGE 
3 1130.50 ± 975.337 
REHOSPITALISATION 2 83.34 ±  57.368 
TOTAL 100 877.62 ±  1900.831 
TROP T 2ND SAMPLE NO EVENTS 94 3464.42 ±  3713.211 
INHOSPITAL 
MORTALITY 
1 1776.00 
MORTALITY ≤ 30 DAYS 
AFTER DISCHARGE 
3 1137.00 ±  887.610 
REHOSPITALISATION 2 756.55 ±  767.140 
TOTAL 100 3323.56 ± 3646.258 
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TABLE 15:  CO-RELATION OF APACHE II SCORE WITH NTTE  
CO-ORDINATES OF THE CURVE 
APACHE II SCORE SENSITIVITY SPECIFICITY 
13.00 89.7% 33.3% 
14.50 88.7% 33.3% 
15.50 85.6% 33.3% 
16.50 81.4% 33.3% 
17.50 77.3% 33.3% 
18.50 72.2% 67.33% 
19.50 70.1% 67.7% 
20.50 67.0% 67.7% 
21.50 61.9% 67.7% 
22.50 59.8% 67.7% 
23.50 50.5% 67.7% 
24.50 47.4% 67.7% 
25.50 46.4% 100% 
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FIGURE 11:  ROC CURVE 
 
Area Under the Curve 
Test Result Variable:  APACHE II SCORE  
Area Std. Error P value 
95% Confidence Interval 
Lower Bound Upper Bound 
0.722 0.119 0.192 0.488 0.955 
• APACHE II score ≥18 in critically ill MICU patients was associated with NTTE 
with 72% sensitivity and 67.33% specificity. While APACHE II score ≥ 25 was 
associated with NTTE with 100% specificity and sensitivity decreased to 46.4%. 
• Co-relation between APACHE II score and NTTE was not statistically 
significant (Area under curve- 0.722; p value-0.192; 95% CI- 0.488-0.955%). 
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TABLE 16A: COMPARISON OF FEMALE SEX WITH IN-HOSPITAL MORTALITY 
AMONG NTTE AND THROMBOTIC ACS PATIENTS  
FEMALE THROMBOTIC 
ACS 
NTTE TOTAL P VALUE 
MORTALITY 5 (45.5%) 6 (54.5%) 11 0.751 
ALIVE 14 (36.8%) 24(63.2%) 38 
TOTAL 19 30 49 
 
TABLE 16B: COMPARISON OF FEMALE SEX WITH IN-HOSPITAL MORTALITY 
AMONG NTTE AND THROMBOTIC ACS PATIENTS  
MALE THROMBOTIC 
ACS 
NTTE TOTAL P VALUE 
MORTALITY 6 (33.3%) 12 (67.3%) 18 0.251 
ALIVE 17 (51.5%) 16(48.5%) 33 
TOTAL 23 28 51 
 
• I t is revealed in table that the co-relation between sex and in-hospital mortality 
in NTTE and thrombotic ACS patients in MICU group was not statistically 
significant. 
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TABLE 17: CO-RELATION OF IN-HOSPITAL MORTALITY IN THROMBOTIC ACS 
AND NTTE SUBGROUPS. 
GROUPS THROMBOTIC 
ACS 
NTTE TOTAL P VALUE 
IN- HOSPITAL 
MORTALITY 
11 (37.9%) 18 (62.1%) 29 0.669 
ALIVE 31 (43.7%) 40 (56.3%) 71 
TOTAL 42 58 100 
 
FIGURE 12:  
 
Table and bar diagram showing no statistically significant co-relation between in-
hospital mortality in thrombotic ACS patients and NTTE patients 
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FIGURE 13A: KAPLAN - MEIER ANALYSIS CURVE FOR TROPONIN T BASELINE 
SAMPLE: 
 
• Kaplan-Meier analysis curves for troponin T 1st sample: suggesting that higher 
the serum troponin level higher is the mortality. 
 
 
 
 
 
 
71 
 
FIGURE 13B: KAPLAN- MEIER ANALYSIS CURVE FOR TROPONIN T 2ND SAMPLE: 
 
 
 
• Kaplan-Meier analysis curves for troponin T 2nd sample: suggesting that higher 
the serum troponin level higher is the mortality.  
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TABLE 18A: TABLE SHOWING INCIDENCE OF ≥ 3 PREDICTORS OF ACS IN MICU 
GROUP (chest pain, abnormal ECG, abnormal ECHO suggestive of ACS and troponin 
level change ≥20% from baseline sample) 
 Thrombotic ACS NTTE Total 
≥ 3 Predictors of 
ACS are present 
42 30 72 
< 3 Predictors of 
ACS are present 
0 28 28 
Total 42 58 100 
 
TABLE 18B: PROBABILITY OF ACS IF ≥ 3 PREDICTORS OF ACS ARE PRESENT. 
 Percentages and 
ratios 
               95% Confidence interval 
Lower limit Upper limit 
Sensitivity 100% 91.51% 100% 
Specificity 48.28% 34.95% 61.78% 
Positive Likelihood 
Ratio 
1.93 1.51 2.48 
Disease Prevalence 42% 32.20% 52.29% 
Positive predictive 
value 
58.33% 46.11% 69.85% 
Negative predictive 
value 
100 87.54% 100% 
 
• When ≥ 3 predictors are present the patient was diagnosed as having ACS. 
•  For diagnosing ACS this gives us a sensitivity of 100%, specificity of 
48.25%, positive predictive value of 58.33%, negative predictive value of 
100% and positive likelihood ratio of 1.93. 
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TABLE 19A: TABLE SHOWING INCIDENCE OF ≥ 3 PREDICTORS OF ACS IN MICU 
GROUP (chest pain, abnormal ECG, ECHO suggestive of ACS and at least one troponin 
value > 300 pg/ml or ng/lt.) 
 Thrombotic ACS NTTE Total 
≥ 3 Predictors of 
ACS are present 
42 13 55 
< 3 Predictors of 
ACS are present 
0 45 45 
Total 42 58 100 
 
TABLE 19B: PROBABILITY OF ACS IF ≥ 3 PREDICTORS OF ACS ARE PRESENT. 
 Percentages and 
ratios 
               95% Confidence interval 
Lower limit Upper limit 
Sensitivity 100% 91.51% 100% 
Specificity 77.59% 64.72% 87.48% 
Positive Likelihood 
Ratio 
4.46 2.76 7.2 
Disease Prevalence 42% 32.20% 52.29% 
Positive predictive 
value 
76.36% 62.98% 86.76% 
Negative predictive 
value 
100 92.05% 100% 
 
• At least one serum troponin level > 300 pg/ml or ng/L  was used instead of 
≥ 20% troponin change from baseline sample as predictors of ACS in the 
study.  
• For diagnosing ACS there was similar sensitivity (100%) but increase in 
specificity, positive predictive value and positive likelihood ratio (77.59% 
vs. 48.25, 76.36% vs. 58.33 and 4.46 vs. 1.93 respectively). 
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TABLE 20A: DIVISION OF NTTE AND THROMBOTIC ACS PATIENTS INTO 
GROUPS AS PER APACHE II SCORE  
APACHE II SCORE THROMBOTIC ACS NTTE TOTAL P VALUE 
≥ 12 TO 17 5 (21.7%) 18 (78.3%) 23 
.074 ≥ 18 TO 24 14 (45.2%) 17 (54.8%) 31 
≥ 25 23 (50%) 23 (50%) 46 
 
FIGURE 14: PIE DAIAGRAM SHOWING DISTRIBUTION OF PATIENTS INTO 
GROUPS AS PER APACHE II SCORE. 
TABLE 20B: COMPARISON OF THROMBOTIC ACS AND NTTE GROUP AS PER  
APACHE II SCORE 
APACHE II SCORE NTTE THROMBOTIC ACS TOTAL P VALUE 
≥ 25 23 (56.1%) 23(82.14%) 46 0.022 
≥ 12 TO 17 18 (43.9%) 5 (17.86%) 23 
TOTAL 43 28 69 
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TABLE 20C: PROBABILITY OF NTTE WHEN APACHE II SCORE IS ≥ 25  
 Percentages and ratios 95% Confidence Interval 
Lower Upper 
Sensitivity 56.10% 39.75% 71.52% 
Specificity 17.86% 6.13% 36.91% 
Positive Likelihood ratio 0.68 0.50 0.94 
Negative Likelihood ratio 2.46 1.03 5.85 
Disease Prevalence 59.52% 46.92% 71.08% 
Positive Predictive Value 50% 34.91% 65.09% 
Negative Predictive Value 21.74% 7.54% 43.71% 
 
• Critically ill patients with elevated troponin levels having APACHE II 
score ≥ 25 were compared to (≥ 12 to 17). 
• Our result showed that critically ill patients with elevated troponin level, 
having APACHE II score with in 24 hour of admission to ICU of ≥ 25 
there is 50% probability that patient is having NTTE. 
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TABLE 20D: PROBABILITY OF NTTE WHEN APACHE II SCORE IS ≥ 12 TO 17  
 Percentages 
and ratios 
95% Confidence Interval 
Lower Upper 
Sensitivity 43.90% 28.48% 60.25% 
Specificity 82.14% 63.09% 93.87% 
Positive Likelihood ratio 2.46 1.03 5.85 
Negative Likelihood ratio 0.68 0.5 0.94 
Positive Predictive Value 78.26% 56.29% 92.46% 
Negative Predictive Value 50% 34.91% 65.09% 
 
• Our result showed that critically ill patients with elevated troponin level, 
having APACHE II score with in 24 hour of admission to ICU of (≥ 12 to 
17) there is 80% probability that patient is having NTTE. 
• In critically ill ICU patients with elevated troponin levels as severity of 
illness increases {as documented by increase in APACHE II score from (≥ 
12 to 17) to ≥ 25)} the probability of NTTE decreases (80% vs. 50%).  
 
 
 
 
 
 
77 
 
 DISCUSSION: 
                 Elevated serum troponin levels are common in critically ill non-cardiac 
patients (CINCP) admitted in MICU. Non-invasive evaluation in such patients is 
difficult to perform and gives limited information. Even after performing coronary 
angiogram in such patients, the decision to label patients as having ACS is difficult if 
there is no clear cut evidence of visible thrombus, slow flow or no flow phenomenon 
visualized on angiogram. These patients may also have coronary artery lesion which 
are stable and longstanding and not contributing to the present condition. It has been 
documented that NTTE is associated with CINCP [S.Agewall et.al, R. Alcali et. al, 
Fleming et. al, Jeremias A et.al, Juan Sanchis et.al, Wallace TW et. al – (10, 20, 
25, 45, 74, and 91 respectively)]. 
                     The present study was aimed to determine the significance of NTTE in 
relation to in- hospital and 30 days mortality, duration of hospitalization and its 
association with non cardiac conditions which are commonly associated with the 
NTTE in CINCP. 200 cases were included in the study, 100 patients of ACS from 
CCU/CPU (56-STEMI and 44-NSTEMI) and 100 critically ill patients from 
MICU/MHDU (42-ACS and 58-NTTE). 
                  One patient (2%) had in-hospital mortality in the CCU-NSTEMI group. In 
MICU group 29 (29%) patients had in-hospital mortality, 11(26.2%) in Thrombotic 
ACS group and 18 (31%) in NTTE group. Both thrombotic ACS and NTTE group had 
higher in-hospital mortality than CCU-NSTEMI patients and this was statistically 
significant (p value = 0.0038 and < 0.001 respectively. NTTE and ACS in critically ill 
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patients had mortality that is to a greater extent higher than that associated with 
STEMI/ NSTEMI patients admitted to CCU/ CPU with no acute medical co-
morbidities (20 to 24). Both NTTE and thrombotic ACS group had increased and 
similar in-hospital mortality despite higher troponin level in thrombotic ACS group (p 
value=0.669). In contrast a similar study done by R Alcalai et.al showed that NTTE 
patients had lower serum troponin level but higher mortality than thrombotic ACS 
patients (24). 
                     In patients who died during index hospitalization baseline troponin T 
level was significantly higher than patients who were discharged alive (699.03 ± 
1953.03 vs. 171.36 ± 233.05 respectively). Baseline troponin level was significantly 
associated with in-hospital mortality (p value 0.026). In patients who died during 
index hospitalization second sample of troponin T was not statistically significantly 
higher than patients who were alive and discharged (681.96 ± 1782.04 vs. 372.42 ± 
652.811 respectively; p value 0.205). 
                  In accordance with our study Ammann et.al showed that elevated troponin 
level is associated with increased in-hospital mortality (19). King DA et.al also 
showed similar prognostic role of elevated troponin in critically ill patients (21). 
Similarly in a study by Wu TT et.al elevated serum troponin levels was a risk factor 
for multiple organ dysfunction (MODS) and mortality in non-cardiac critically ill 
patients (23). Similar results were found by Wendy Lim et.al, Guest TM et.al, 
Christian W.Hamm et.al, Mehta S et.al, Di AE et.al (19, 20, 46, 73 respectively). A 
sub-study of TACTIC-TIMI 18 had shown that 4% of patients who were diagnosed to 
have ACS, on angiogram had normal or no significant coronary artery disease 
79 
 
suggesting false positive troponin test. These patients had significantly higher major 
adverse cardiovascular events than patients without troponin elevation (92). Keller 
et.al stated that higher in-hospital mortality in CINCP is due to fact that these patients 
are sicker and troponin is marker or indicator of a critical state of non-cardiac disease 
condition (93).                     
                        Kaplan-Meier analysis curves for troponin 1st and 2nd sample suggested 
that mortality showed positive correlation with increasing troponin levels. In 
accordance with the result of our study and previous literature serum troponin level 
have prognostic role in CINCP and is associated with MODS and increased in-
hospital mortality. 
           In MICU group 11(22.4%) females had in-hospital mortality (p value= 0.751).  
Similarly 18(26.1%) males had in-hospital mortality (p value= 0.251). Sex was not a 
determinant of in-hospital mortality in CINCP with troponin elevation in MICU 
group. 
                In MICU group, patients with the highest troponin levels had higher 
APACHE II score i.e. more severe medical illness; and early in-hospital death. This 
explains paradoxical result of negative co-relation of baseline elevation of troponin T 
with duration of hospitalization in our study; but the co-relation was not statistically 
significant (Pearson co-relation coefficient = -0.068 and -0.072 respectively; p value = 
0.501 and 0.479 respectively) 
                In accordance with our study Landesberg G et.al showed that patient with 
higher APACHE II score had higher troponin levels and increased mortality (22). 
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When patients with in-hospital mortality (29%) were removed from analysis there was 
positive co-relation between troponin levels and duration of hospitalization but this 
was not statistically significant (Pearson co-relation coefficient = 0.120 and 0.137; p 
value = 0.338 and 0.237 respectively). 
                In CCU-NSTEMI group within thirty day of discharge only one (2%) 
patient died, no patient required re-hospitalization and 42 (98%) patients were alive 
without any complications. In MICU group within thirty day of discharge 9 (13%) 
patients died, 5 (7%) patients had re-hospitalization and 57 (80%) patients were alive 
without any complications. There was increased trend of mortality ≤ 30 days in 
thrombotic ACS and NTTE (MICU group) as compared to CCU group but this was 
not statistically significant (p value = 0.543 and 0.268 respectively).  
                 In MICU group there was a positive trend towards increased mortality or 
re-hospitalization ≤ 30 days after discharge with elevated troponin T but it was not 
statistically significant (p value for baseline and second sample = 0.157 and 0.564 
respectively). Troponin T level in all these patients were as follows; (Mortality ≤ 30 
days vs. Re-hospitalization vs. Alive without complications: Baseline sample = 
148.82 ± 246.54 vs. 161.60 ± 290.18 vs. 169.51 ± 228.38 respectively; Second 
sample = 438.40 ± 964.385 vs. 175.50 ± 324.683 vs. 370.43 ± 624.049 respectively).        
               In harmony with our study Landesberg G et.al showed that elevated 
troponin levels predicted increased 1-month, 6-month, and 2-yr mortality (odds ratio = 
6.0, 3.2, and 2.99, respectively; p < .001) (22). In a study by Maynard C et.al showed 
that critically ill patients with ACS had higher 30-day mortality (odds ratio-2; 
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95%confidece interval, 1.7-2.4; P<.001) (94). Similarly S Hajsadeghi et.al, Relos RP 
et.al, Mcfalls et.al, Antman et.al found that in patients with ACS, cTn provides 
prognostic information and identifies patients at increased risk of mortality (75, 76, 
81, and 95 respectively).  In comparison to other studies our study showed a trend 
towards increased ≤ 30 days mortality but this was not statistically significant due to 
the limited sample size in our study.   
                 In our study troponin T levels (at baseline and within 24 hours of baseline 
sample) in thrombotic ACS (MICU group) patients were significantly higher than 
troponin T levels in NTTE patients (373.04 ± 1124.51 vs. 289.16 ± 1062.26 and 
743.31 ± 1303.90 vs. 258.62 ± 891.41 respectively; p value for Troponin T 1st and 2nd 
sample is 0.05 and 0.000 respectively). Similarly in accordance with our result studies 
by Relos RP et.al, Vasile VC et.al, Altmann et.al, Booker KJ et.al, Wendy Lim 
et.al, Jensen JK et.al, Baillard C et.al also showed an entity of non-thrombotic 
troponin elevation in critically ill patients (76-82, 96 respectively).  
                In our study troponin T baseline and second sample levels in NSTEMI 
patients in CCU group were not statistically significantly higher than troponin T level 
in thrombotic ACS patients in MICU group (347.17 ± 566.90 vs. 373.04 ± 1124.51 
and 983.47 ± 1922.34 vs. 743.31 ± 1303.90 respectively; p value = 0.892 and 0.502 
respectively). Suggesting that serum troponin levels in NSTEMI patient in CCU and 
ACS patients in MICU were in similar range.  
                      Chest pain, ECG and ECHO changes suggestive of ACS along with ≥ 
20% troponin change from first to second sample were used as predictors of ACS in 
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the study. When ≥ 3 predictors are present the patient was diagnosed as having ACS. 
For diagnosing ACS we found a sensitivity of 100% (95% CI: 91.51% to 100%), 
specificity of 48.25% (95% CI: 34.95% to 61.78%), positive predictive value of 
58.33% (95% CI: 46.11% to 69.85%), negative predictive value of 100% (95% CI: 
87.54% to 100%) and positive likelihood ratio of 1.93 (95% CI: 1.51 to 2.48). In 
CINCP with low pre test probability of CAD the diagnostic accuracy of troponin for 
ACS is only 58%.  
                   When at least one serum troponin level > 300 pg/ml or ng/L was used 
instead of ≥ 20% troponin change from first to second troponin as predictors of ACS 
in the study; for diagnosing ACS we found a sensitivity of 100% (95% CI: 91.1% to 
100%), specificity of 77.59% (95% CI: 64.72% to 87.48%), positive predictive value 
of 76.36% (95% CI: 62.98% to 86.75%) and positive likelihood ratio of 4.46 (95% CI: 
2.76 to 7.20). With the troponin cut off > 300 pg/ml there was similar sensitivity and 
NPV (100%) for diagnosing ACS but there was increase in specificity, positive 
predictive value and positive likelihood ratio (77.59% vs. 48.25, 76.36% vs. 58.33 and 
4.46 vs. 1.93 respectively).  
                  Thus in critically ill patients with abnormal ECG and ECHO suggestive of 
ACS and at least one serum troponin level ≥300 pg/ml or ng/L within 48 hours of 
admission to intensive care unit; ACS can be diagnosed with 100% sensitivity and 
77% specificity. Our study shows that in critically ill patients, elevated troponin 
values (more than twenty times above the 99th percentile of URL) can occur without 
acute coronary syndrome. The results of our study substantiate the evidence that 
increase in cTnT is common in CINCP as they are suffering from large range of 
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underlying medical illness. As per our study in CINCP with low pre test probability of 
CAD, even if troponin level cut off for diagnosing thrombotic ACS is taken as 300 
ng/L (> 20 times above the 99th percentile of URL); 22% patients can still have NTTE 
and not acute coronary syndrome.   
                Patients were classified according to APACHE II score into three- groups. 
Critically ill patients with elevated troponin levels having APACHE II score ≥ 25 
were compared to (≥ 12 to 17). Our study shows that in critically ill patients with 
APACHE II score ≥ 25 with elevated troponin level, the probability that the patient 
has NTTE is only 50%. For diagnosing NTTE in patients with APACHE II score ≥ 
25; the sensitivity was only 56.10% (95% CI: 39.75% to 71.52%), specificity was 
17.86% (95% CI: 6.13% to 36.91%), positive predictive value was 50% (95% CI: 
34.91% to 65.09%), disease prevalence was 59.52% (95% CI: 46.92% to 71.08%) and 
Negative predictive value was 21.74% (95% CI: 7.54% to 43.71%).  
                        Similarly for diagnosing NTTE in patients with APACHE II score (≥ 
12 to 17) there was sensitivity of 43.90% (95% CI: 28.48% to 60.25%), specificity of 
82.14% (95% CI: 63.29% to 92.87%), Positive Predictive value of 78.26% (95% CI: 
56.29% to 92.46%), Positive Likelihood ratio of 2.46 (95% CI: 1.03 to 5.85), disease 
prevalence of 59.52% (95% CI: 46.92% to 71.08%) and Negative predictive value of 
50 %. (95% CI: 34.91% to 65.09%). This was statistically significant (p value = 
0.022). Our result showed that critically ill patients with elevated troponin level 
having APACHE II score ≥ 12 to 17 within 24 hour of admission to ICU; the 
probability that the patient is having NTTE is 80%.  
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                   In critically ill ICU patients with elevated troponin levels as severity of 
illness increases {as documented by increase in APACHE II score from (≥ 12 to 17) to 
≥ 25)} the probability of NTTE decreases (80% to 50%). This can be explained as 
critically ill patients have multiple stressors and pro-coagulant conditions which 
increases as patient becomes more severely ill {as documented by increase in 
APACHE II score from (≥ 12 to 17) to ≥ 25)}can cause acute progression in severity 
of pre-existing coronary artery lesion (Type 1 MI). There can also be concomitant cell 
damage from hypo-perfusion or hypoxia of non coronary etiology (Type 2 MI) 
making simultaneous occurrence of both types of MI a possibility (8). 
                      Renal failure was present in 15 patients (15%) in CCU group and 63 
patients (63%) in MICU group. In MICU group renal failure was present in 23 cases 
(54.76%) in ACS and 40 cases (68.97%) in NTTE group. There was a positive trend 
between renal failure and troponin elevation in NTTE patients as compared to ACS 
patients but the association was not statistically significant (LR- 1.86; p value 0.147; 
Odds ratio-1.836; 95%CI - 0.805 -4.184%). In accordance with our finding a study by 
R. Alcalai et.al found that renal failure was significantly associated with troponin 
elevation, favoring NTTE (p value=0.03) (24). Landesberg G et.al found renal 
failure associated with troponin elevation (22). In presence of renal failure in CINCP 
the probability of NTTE is high as compared to thrombotic ACS (24, 45).                  
                        Past history of coronary artery disease was present in 21 patients (21%) 
in CCU group and 18 patients (18%) in MICU group. In MICU group past history of 
coronary artery disease was present in 9 cases (50.00%) in ACS and 9 cases (50.00%) 
in NTTE group. It showed a positive trend between past history of CAD and 
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thrombotic ACS but it was not statistically significant (LR-4.382, p value 0.451; Odds 
ratio-0.673; 95% CI - 0.242 -1.875%).  In harmony with our result study by R. 
Alcalai et.al showed that past history of coronary artery disease was significantly 
associated with troponin elevation, favoring thrombotic ACS (p value=0.05) (24) 
                    Diabetes mellitus was present in 46 patients (46%) in CCU group and 48 
patients (48%) in MICU group. In MICU group DM II was present in 21 cases 
(45.65%) in ACS and 25 cases (54.35%) in NTTE group. It was non-significantly 
associated with troponin elevation in NTTE patients (Likelihood Ratio (LR) -2.485; p 
value 0.416; Odds ratio-0.812; 95% confidence interval (CI) - 0.367 – 1.801%). R. 
Alcalai et.al had shown that DM II was not statistically significantly associated with 
troponin elevation, favoring thrombotic ACS (p value=0.42) (24). 
                  Hypertension was present in 50 patients (50%) in CCU group and 49 
patients (49%) in MICU group. In MICU group hypertension was present in 24 cases 
(48.98%) in ACS and 25 cases (51.02%) in NTTE group. It was non-significantly 
associated with troponin elevation in NTTE patients (LR- 1.712; p value 0.191; Odds 
ratio-0.586; 95% CI- 0.262 -1.310%). R. Alcalai et.al had shown that hypertension 
was significantly associated with troponin elevation, favoring NTTE (p value=0.03) 
(24) 
                          In the present study, the medical diagnosis which were most 
commonly associated with NTTE includes Sepsis (77.59%), ARF (68.97%), Anemia 
(43.10%), Shock (Septic or hypo-volumic- 31.03%), Pneumonia (25.86%), ARDS 
(20.69%), Myocarditis (12.07%), CHF (10.34%), Tachyarrhythmia (6.9%), CPR 
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(6.9%), COPD (3.49%), Brady-arrhythmia, RHD, CVA, AIDP, Diabetic ketoacidosis, 
GTCS, Snake bite (Each 1.72%). 
               Out of 100 cases in CCU/CPU group there were 81 males (81%) and 19 
females (19%). Male sex was statistically significantly associated with ACS in CCU 
group (P value 0.05). In STEMI patients there were 51 males (9.1%) and 5 females 
(8.9%). In NSTEMI patients there were 30 males (68.2%) and 14 females (31.8%). 
Mean age of cases in CCU/CPU group was 55.7 ± 16.86 years. NSTEMI cases were 
significantly older than STEMI cases (63.59 ± 10.957 vs. 53.16 ± 10.133, p value 
0.000). 
                    Out of 100 cases in MICU/MHDU group there were 51 male (51%) and 
49 females (49%). In NTTE group 28 patients were males (48%) and 30 patients were 
females (52%). Sex was not significantly associated with troponin elevation in NTTE 
patients (LR-0.411, p value 0.522). In harmony to our result a study done by R. 
Alcalai et.al showed that sex was not significantly associated with troponin elevation, 
favoring thrombotic ACS (p value=0.94) (24). 
                    Mean age of cases in MICU/MHDU group was 57.75 ± 11. 67 years.  
NTTE cases were non-significantly younger than ACS cases (53.16 ± 18.32 vs. 59.21 
± 14.08; p value 0.076). In disagreement to our study R. Alcalai et.al  showed that 
age between 40 to 80 years was significantly associated with troponin elevation, 
favoring thrombotic ACS (p value=0.03 to 0.001) (24)  
                         In conclusion elevated serum troponin level is a common presentation 
in critically ill ICU patients even without any evidence of ACS or with normal 
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epicardial coronaries or without flow limited coronary artery disease (1, 8, and 20). 
Our study showed that 50% of critically ill patients with multiple co-morbid 
conditions with elevated troponin values had non-thrombotic troponin elevation. 
Increased in-hospital and thirty day mortality in NTTE patients in our study 
substantiates that NTTE patients have worse prognosis as compared to critically ill 
patients without troponin elevation (20 to 24). Elevated troponin levels needs to be 
evaluated in clinical scenario and pre test probability before diagnosing them as 
having ACS and starting them on treatment for ACS (7). There is no evidence that 
treatment modalities for thrombotic ACS will be beneficial for NTTE in CINCP 
having low pre test probability of coronary artery disease (24, 45).  
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LIMITATIONS: 
1) The major limitation of this study was the fact that diagnosis of patients having 
NTTE or thrombotic ACS is subjected to misclassification bias. Coronary 
angiogram was done in only limited number of critically ill patients due to 
relative contraindications from their medical diseases. As coronary anatomy is 
not delineated the diagnosis of ACS could not be confirmed and this can lead to 
misclassification bias. To minimize this classification of patients into NTTE 
and thrombotic ACS was done after careful clinical evaluation of patient and 
with maximal adherence to ACC/AHA and ESC guidelines. The diagnosis was 
supported by objective evidence such as ECG and Echocardiogram.  
2) Though the sample size was calculated using appropriate statistical methods, 
but it was not powered enough to assess the association of traditional risk 
factors as independent predictors of NTTE. A larger sample size and study will 
give better and more consolidated information regarding this unique entity: 
NTTE and its association with traditional risk factors. 
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SUMMARY AND CONCLUSIONS: 
                The study was undertaken in Department of Cardiology and Medicine- 
Division of Critical Care, Christian Medical College Vellore. The present study is 
done to assess relationship of thrombotic and non-thrombotic troponin elevation. It 
was aimed to measure serum troponin levels in critically ill patients in MICU/MHDU 
and ACS patients in CCU/CPU and to correlate it with duration of hospitalization, in-
hospital and 30 days mortality. 200 cases were selected in the study, 100 patients of 
ACS from CCU/CPU (56-STEMI and 44-NSTEMI) and 100 critically ill patients 
from MICU/MHDU (42-ACS and 58-NTTE) respectively in our hospital. The study 
was conducted over a period of 18 months from August 2013 to December 2014 in the 
department of Cardiology and Medicine- Critical Care division. 
Following conclusions were drawn from the study performed: 
1) Baseline Troponin T level was significantly associated with in-hospital 
mortality in critically ill medical patients (p value 0.026). 
2) In critically ill patients with abnormal electrocardiogram and echocardiogram 
suggestive of ACS, with serum Troponin levels ≥300 pg/ml or ng/L within 48 
hours of admission to intensive care unit; ACS can be diagnosed with 100% 
sensitivity and 77% specificity. 
3) Our study shows that in critically ill patients with APACHE II score ≥ 25 with 
elevated troponin level, the probability that the patient has NTTE is only 50%. 
In critically ill ICU patients with elevated troponin levels, as the severity of 
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illness increases {as documented by increase in APACHE II score from (≥ 12 
to 17) to ≥ 25)} the probability of NTTE decreases (80% to 50%). 
4) In CINCP with low pre test probability of CAD, the diagnostic accuracy of 
serum troponin for ACS when used in isolation is only 58%. 
5) Troponin T level in ACS patients was significantly higher than troponin T level 
in NTTE patients (p value for Troponin T 1st and 2nd sample is 0.05 and 0.000 
respectively). However the in-hospital mortality in the two subgroups were 
comparable (26% vs. 31%; p value = 0.667). 
6)  Troponin T level in NSTEMI patients in CCU group was not significantly 
higher than troponin T level in ACS patients in MICU group (p value= 0.892 
and 0.502 respectively). Suggesting serum troponin levels in NSTEMI patient 
in CCU and ACS patients in MICU were in similar range.  
7) In the present study, the medical diagnoses which were most commonly 
associated with NTTE includes Sepsis (77.59%), ARF (68.97%), Anemia 
(43.10%), Shock (Septic or hypo-volumic- 31.03%), Pneumonia (25.86%), 
ARDS (20.69%), Myocarditis (12.07%), CHF (10.34%), Tachyarrhythmia 
(6.9%), CPR (6.9%), COPD (3.49%). 
Our findings resonate with the findings and conclusion of numerous studies 
done all over the world in the last two decades. This is the first study of its sort 
done on Indian population. Further research should be done in future and 
criteria should be defined by ACC/ AHA and ESC to diagnose NTTE in 
critically ill ICU patients and guidelines should be given for its management. 
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APPENDIX- I 
ABBREVIATION 
MICU: Medical Intensive Care Unit. 
MHDU: Medical High Dependency Unit. 
CCU: Coronary Care Unit. 
CPU: Chest Pain Unit. 
ACS: Acute Coronary Syndrome. 
STEMI: ST Elevation Myocardial Infarction. 
NSTEMI: Non ST Elevation Myocardial Infarction. 
UA: Unstable angina 
NTTE: Non Thrombotic Troponin Elevation. 
CINCP: Critically ill non cardiac patients. 
CKMB: Creatinine Kinase Muscle Brain 
LDH: Lactate dehydrogenase 
CAD: Coronary artery disease 
cTnT: Cardiac Troponin T 
cTnI: Cardiac Troponin I 
RWMA: Regional wall motion abnormality. 
ARDS: Acute respiratory distress syndrome. 
ICD: International Classification of Diseases  
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX II-A 
PATIENT CONSENT FORM 
Study Title: Assessment of thrombotic and non-thrombotic troponin elevation 
 
Study Number: 
Participant’s Name:  
Date of Birth / Age (years): 
 
Please tick boxes 
(i) I confirm that I have read and understood the information sheet dated _________ 
for the above study and have had the opportunity to ask questions. [    ] 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [    ] 
(iii) I understand that the Ethics Committee and the regulatory authorities will not need 
my permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
trial. I agree to this access. However, I understand that my identity will not be revealed 
in any information released to third parties or published. [    ] 
(iv) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [     ] 
(v) I agree to take part in the above study. [     ] 
Signature of the Subject/ 
Legally Acceptable Representative: ____________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name of the Witness: ______________________________ 
 
(Or Thumb impression) 
APPENDIX II-B 
TOPIC:  Assessment of thrombotic and non thrombotic troponin elevation 
CASE STUDY PROFORMA 
CASE STUDY No: 
NAME: 
FATHER’S/ HUSBAND’S NAME: 
CMC HOSPITAL NO.: 
AGE AND SEX: 
MARITAL STATUS: 
ADDRESS: 
PHONE NO.:    MOBILE NO:                                            LANDLINE NO: 
DATE OF ADMISSION: 
DATE OF ENROLLMENT: 
PLACE OF ADMISSION:  CCU / CPU / MICU / MHDU 
CHEST PAIN:      YES / NO  
     A) TYPICAL-ALL THREE PRESENT       
  B) ATYPICAL-LESS THAN THREE PRESENT 
            a) SUBSTERNAL CHEST PAIN  
            b) DISCOMFORT PROVOKED BY EXERTION AND /OR EMOTIONAL        
STRESS   
            c) WAS RELIEVED WITH REST AND/OR NITROGLYCERINE                                                   
 CLINICAL DIAGNOSIS AT ADMISSION: 
 RISK ASSESSMENT  
HYPERTENTION   :        YES / NO 
DIABETES MELLITUS  :    YES / NO 
HISTORY OF SMOKING  :     YES / NO     IF YES: ACTIVE /REFORMED 
HISTORY OF CARDIOVASCULAR 
DISEASE (ACS/CVA) IN PAST :  YES  /  NO 
HYPOTHYROIDISM  :  YES / NO 
DYSLIPIDEMIA   :  YES / NO        
RENAL FAILURE   : YES / NO            eGFR:               ml/min/1.73m2 
PATIENT INTUBATED AND VENTILATED : YES / NO           IF YES: PEEP- 
 
EXAMINATION FINDINGS AT ADMISSION 
JVP   -    RAISED/NOT RAISED 
TEMPERATURE -           
PULSE-                /MIN                      REGULAR/IRREGULAR 
ALL PERIPHERAL PULSES PALPABLE - YES / NO 
BP-           /         MMHG    
RESPIRATORY   RATE -             /MIN 
RS-     CLEAR / RHONCHI / CREPTS   
CVS-   S1 -          S2- 
           S3- YES / NO           S4- YES / NO 
           MURMUR----     YES / NO  
ETIOLOGY 
A) THROMBOTIC CORONARY ARTERY DISEASE   (ACS):  YES / NO  
B) NON THROMBOTIC CONDITIONS WITH TROPONIN ELEVATION: YES/NO  
1) COPD 
2) PULMONARY EMBOLISM 
3) ARDS 
4) PULMONARY OEDEMA 
5) INTRACRANIAL HEMMORRHAGE/SUBDURAL HAEMATOM/SAH 
6) CVA 
7) HYPOTENTION/SHOCK 
8) ACUTE/CHRONIC RENAL FAILURE   
9) HYPOVOLUEMIA 
10) SEPSIS  
11) ANAEMIA 
12) CARDIAC CONTUSION 
13) ACUTE GASTROINTESTINAL BLEED 
14) ACUTE PANCREATITIS 
15) HYPERCARBIA 
16) HYPOXIA 
17) DIABETIC KETOACIDOSIS 
18) ACUTE AORTIC DISSECTION 
19) ACUTE HEART FAILURE 
20) PERIMYOCARDITIS 
21) ENDOCARDITIS 
22) TAKO-TSUBO CARDIOMYOPATHY 
23) TACHYARRHYTHMIAS  /  BRADYARRHYTHMIA 
24) RADIOFREQUENCY CATHETER ABLATION  
25) TRAUMA 
26) CATECHOLAMINES  /SYMPATHOMIMETICS 
27) CHEMOTHERAPY  INDUCED 
28) HIGH PEAK END EXPIRATORY PRESSURE 
29) OTHER CONDITION THAN LISTED 
      
INVESTIGATIONS:  
1) HEMOGLOBIN- 
2) HEMATOCRIT- 
3) TLC –  
4) DLC-- 
N E L B M 
     
   
5) PLATELET COUNT- 
6) SERUM SODIUM- 
7) SERUM POTASSIUM- 
8) SERUM CREATININE- 
9) BLOOD UREA 
 
 
 
10) LIPIDS :  
TOTAL 
CHOLESTEROL 
TRIGLYCERIDES HDL LDL 
    
    
 
NON HDL CHOLESTEROL- 
11) RANDOM  BLOOD GLUCOSE LEVEL ATADMISSION- 
12) HBA1C- 
13) TSH- 
14) CKMB 
HOURS WITHIN 24 HOURS OF 
ADMISSION 
WITHIN 24 HOURS OF 
FIRST SAMPLE 
LEVELS   
 
15) TROPONIN -    
HOURS WITHIN 24 HOURS OF 
ADMISSION 
WITHIN 24 HOURS OF 
FIRST SAMPLE 
LEVELS   
 
 
 
16) ECG :     a)  NEW ONSET LBBB  -  YES  /  NO 
                b) T WAVE INVERSION -  YES / NO                                 LEADS- 
                c) ST SEGMENT DEPRESSION - YES / NO                      LEADS- 
                d) ST SEGMENT ELEVATION - YES / NO                        LEADS- 
                e) Q WAVES-    YES / NO         NEW ONSET / OLD      LEADS – 
    
17) ECHO :        LVEF-               ,  MR-                ,TR-                    ,PE-            
                  RWMA-                  LVIDs-                LVIDd-                        LA- 
                     LVD -     YES / NO,    IF YES---MILD /MODERATE / SEVERE 
18) CORONARY ANGIOGRAPH (WHEN APPLICABLE)-                                                             
a) CULPRIT   LESION     a)   ≥80% STENOSIS 
                                           b) THROMBUS CONTAINING LESION 
                                        c)   ≤ TIMI II FLOW 
     b) LEFT MAIN 
     c) LEFT ANTERIOR DESCENDING 
     d)  LEFT CIRCUMFLEX 
     e) RIGHT CORNARY 
     f) INTERVENTION DONE- 
19) APACHE II SCORE  FOR MICU PATIENTS  - 
                 a) ACUTE PHYSIOLOGY SCORE 
                 b) GLASGOW COMA SCORE 
                 c) POINTS FOR AGE 
                 d) CHRONIC HEALTH CONDITIONS 
  
 DISCHARGE DIAGNOSIS - 
 
INHOSPITAL OUTCOME - 
a)  IN HOSPITAL MORTALITY :   YES/ NO 
b)    MYOCARDIAL INFARCTION  :  YES / NO                           
                      IF YES                               STEMI / NSTEMI 
c)     CAG AND URGENT REVASCULARISATION - YES / NO 
 
OUTCOME ≤30 DAYS AFTER DISCHARGE - 
a) MORTALITY     :  YES  /  NO 
 
b) REHOSPITALISATION   :  YES  /  NO       
       IF YES-        WITHIN HOW MANY DAYS OF DISCHARGE- 
 
c)   RE INFARCTION   :   YES / NO 
 
SN HOSP NO AGE SEX DT OF           ADMISSION
DATE OF 
ENROLLMENT PLACE
CHEST 
PAIN
TYPE OF 
CHEST PAIN
DIAGNOSIS AT 
ADMISSION KILLIP HTN DM II SMOKER
HYPOTHYROI
DISM
DYSLIPIDE
MIA
PAST H/O 
CAD 
RENAL 
FAILURE
INTUBATE
D 
1 713702F 50 M 13/11/2013 13/11/2013 CCU 1 1 IWMI I 2 2 2 2 1 2 2 2
2 713701F 65 M 13/11/2013 13/11/2013 CCU 1 1 AWMI IV 1 1 2 2 1 2 1 2
3 713709F 54 M 13/11/2013 13/11/2013 CPU 1 1 IWMI, PWMI, RVMI II 2 1 2 2 1 2 2 2
4 708552F 70 F 13/11/2013 13/11/2013 CPU 2 3 NSTEMI 1 1 2 2 1 1, CVA 1 2
5 713710F 65 M 13/11/2013 13/11/2013 CPU 1 1 IWMI,RVMI II 1 2 2 2 1 2 2 2
6 159355F 53 M 15/11/2013 15/11/2013 CPU 1 1 IWMI,RVMI,PWMI I 2 2 1 2 1 2 2 2
7 713756F 65 F 14/11/2013 15/11/2013 CPU 1 2 NSTEMI 1 1 2 2 1 2 2 2
8 649442C 50 M 15/11/2013 15/11/2013 CPU 1 1 ASMI II 1 1 2 2 1 1, ACS 1 2
9 569119B 56 M 15/11/2013 15/11/2013 CCU 1 1 NSTEMI 2 2 1 2 1 1, ACS 2 2
10 720081F 44 M 17/11/2013 17/11/2013 CPU 1 2 AWMI II 2 2 1 2 2 2 2 2
11 275103D 31 M 17/11/2013 17/11/2013 CPU 1 1 AWMI I 2 2 1 2 1 2 2 2
12 720101F 51 M 17/11/2013 17/11/2013 CPU 1 1 IWMI I 2 2 1 2 1 2 2 2
13 121465B 78 F 17/11/2013 17/11/2013 CCU 1 2 NSTEMI 1 1 2 2 1 2 2 2
14 720097F 66 F 17/11/2013 18/11/2013 CCU 1 2 NSTEMI 2 2 1 2 1 2 2 2
15 720143F 34 M 18/11/2013 19/11/2013 CCU 1 1 AWMI I 2 1 2 2 1 2 2 2
16 720130F 72 M 18/11/2013 19/11/2013 CCU 1 1 AWMI II 1 2 2 2 2 2 2 2
17 903164C 52 M 18/11/2013 19/11/2013 CCU 1 2 NSTEMI 2 2 2 2 1 2 2 2
18 720179F 52 M 19/11/2013 19/11/2013 CPU 1 1 AWMI I 2 2 2 2 2 2 2 2
19 510679B 38 M 23/11/2013 24/11/2013 CCU 1 1 AWMI II 2 2 1 2 1 2 2 2
20 623867F 70 M 24/11/2013 25/11/2013 CCU 1 1 NSTEMI 1 1 2 2 1 1, ACS 2 2
21 720649F 50 M 24/11/2013 25/11/2013 CCU 1 1 NSTEMI 1 2 1 2 1 1, ACS 2 2
22 655540F 71 M 24/11/2013 25/11/2013 CCU 2 3 NSTEMI 2 2 2 1 1 1, ACS 1 1
23 720623F 57 M 24/11/2013 25/11/2013 CPU 1 1 AWMI II 1 2 1 2 2 2 2 2
24 720624F 71 M 24/11/2013 25/11/2013 CPU 1 1 IWMI,RVMI I 2 2 2 2 1 2 2 2
25 294719B 44 M 22/11/2013 23/11/2013 CCU 2 3 NSTEMI 1 2 2 2 2 2 2 2
26 720735F 59 M 25/11/2013 26/11/2013 CCU 1 1 AWMI I 2 2 2 2 1 2 2 2
27 720769F 50 F 26/11/2013 26/11/2013 CPU 1 2 IWMI, RVMI, PWMI I 2 1 2 2 1 2 2 2
28 720731F 80 F 25/11/2013 26/11/2013 CPU 2 3 IWMI, PWMI I 1 2 2 2 1 2 1 2
29 408888D 51 M 27/11/2013 28/11/2013 CCU 1 1 AWMI I 2 1 2 1 1 2 2 2
30 151157D 76 F 27/11/2013 27/11/2013 CCU 1 1 IWMI,RVMI, PWMI I 1 1 2 2 2 2 2 2
31 622344F 65 F 28/11/2013 29/11/2013 CCU 1 1 IWMI I 1 2 2 1 1 2 2 2
32 791763B 79 M 29/11/2013 29/11/2013 CCU 2 3 NSTEMI 1 1 1 2 1 1, ACS 1 2
33 384654F 59 M 28/11/2013 29/11/2013 CCU 2 3 NSTEMI 2 2 1 2 1 1, ACS 2 2
34 720801F 62 M 29/11/2013 29/11/2013 CCU 1 1 STEMI I 2 1 1 2 1 1, ACS 1 2
35 740095F 51 M 10/12/2013 11/12/2013 CPU 1 1 AWMI II 2 2 2 2 2 2 2 2
36 740214F 48 M 11/12/2013 12/12/2013 CPU 1 1 AWMI I 2 2 1 2 1 2 2 2
37 726959F 54 M 11/12/2013 11/12/2013 CPU 1 1 AWMI I 2 2 2 2 2 2 2 2
38 726987F 65 M 11/12/2013 12/12/2013 CPU 1 1 AWMI I 2 2 2 2 2 2 2 2
39 740235F 50 M 12/12/2013 13/12/2013 CPU 1 1 NSTEMI 2 2 1 2 1 2 2 2
40 740247F 70 M 12/12/2013 13/12/2013 CPU 2 3 NSTEMI 1 1 1 2 1 1, ACS 2 2
41 824266C 52 M 13/12/2013 14/12/2013 CPU 1 2 AWMI I 1 1 1 2 1 2 2 2
42 740625F 50 M 15/12/2013 16/12/2013 CPU 1 1 IWMI, PWMI I 1 2 1 2 1 2 2 2
43 893481C 52 M 15/12/2013 16/12/2013 CCU 1 1 IWMI II 2 2 1 2 1 1, ACS 2 2
44 740651F 37 M 16/12/2013 16/12/2013 CPU 1 1 AWMI I 1 2 1 2 1 2 2 2
45 743754F 52 M 16/12/2013 17/12/2013 CCU 1 2 NSTEMI 1 1 1 2 1 2 2 2
46 740757F 48 M 17/12/2013 18/12/2013 CPU 1 2 IWMI I 1 1 2 2 1 2 2 2
47 740761F 67 F 17/12/2013 18/12/2013 CPU 1 1 NSTEMI 1 1 2 2 1 2 2 2
48 740336F 52 M 18/12/2013 18/12/2013 CPU 1 2 IWMI, RVMI, PWMI I 2 1 1 2 1 2 2 2
49 750456F 40 M 22/12/2013 23/12/2013 CCU 1 1 AWMI I 2 2 1 2 2 2 2 2
50 750448F 43 M 22/12/2013 23/12/2013 CPU 1 2 AWMI I 2 1 2 2 1 2 2 2
51 750500F 50 M 23/11/2013 24/12/2013 CCU 1 1 NSTEMI I 1 2 2 2 1 2 2 2
52 744347D 75 F 25/12/2013 26/12/2013 CPU 2 3 NSTEMI 1 1 2 2 1 2 2 2
53 750411D 53 M 23/12/2013 24/12/2014 CPU 1 1 AWMI I 1 1 1 2 1 2 2 2
54 720775F 28 M 26//12/2013 27/12/2013 CPU 1 1 AWMI I 2 2 1 2 2 2 2 2
55 180276F 62 M 26/12/2013 27/12/2013 CPU 1 2 NSTEMI 1 1 1 2 1 2 1 2
56 591988C 44 M 27/12/2013 27/12/2013 CPU 1 2 NSTEMI 2 2 2 2 1 2 2 2
57 750175F 53 F 27/12/2013 27/12/2013 CPU 1 1 NSTEMI 2 2 2 2 1 2 2 2
58 448582F 60 M 27/12/2013 28/12/2013 CPU 1 2 LATERAL WALL STEMI 2 1 2 2 1 1, ACS 2 2
59 039957D 71 F 28/12/2013 28/12/2013 CPU 1 2 NSTEMI 1 1 2 2 1 1, ACS 2 2
60 750726F 60 M 30/12/2013 31/12/2013 CCU 2 3 NSTEMI 1 1 1 2 1 1, ACS 2 2
61 332918B 80 M 31/12/2013 01/01/2014 CCU 1 1 NSTEMI 1 2 2 2 2 1, ACS 2 2
62 750255F 63 F 28/12/2013 29/12/2013 CPU 1 2 IWMI,PWMI III 1 1 2 2 1 2 2 1
63 751213F 59 F 02/01/2014 03/01/2014 CPU 1 1 IWMI, RVMI I 2 2 2 2 1 2 2 2
64 062059F 57 M 01/01/2014 02/01/2014 CPU 1 1 AWMI I 2 2 1 2 1 2 2 2
65 751272F 59 M 06/01/2014 06/01/2014 CCU 1 1 NSTEMI 2 2 2 2 1 2 2 2
66 570803D 52 M 06/01/2014 07/01/2014 CCU 1 2 IWMI I 2 1 1 2 1 2 2 2
67 984562D 61 M 06/01/2014 07/01/2014 CPU 1 2 IWMI I 1 1 2 2 1 2 2 2
68 750818F 59 M 04/01/2014 05/01/2014 CPU 1 2 IWMI I 2 2 2 2 1 2 2 2
69 751298F 65 M 06/01/2014 07/01/2014 CPU 1 1 IWMI, RVMI I 1 1 2 2 1 2 2 2
70 166379F 59 M 08/01/2014 08/01/2014 CCU 1 2 NSTEMI 1 1 2 1 2 2 2 2
71 243871C 63 M 07/01/2014 08/01/2014 CCU 1 1 AWMI II 1 2 1 2 1 2 2 2
72 751467F 74 F 09/01/2014 10/01/2014 CPU 1 1 NSTEMI 1 2 2 2 1 2 2 2
73 423954C 66 M 09/01/2014 10/01/2014 CPU 1 1 NSTEMI 2 1 1 2 1 2 2 2
74 209951D 45 M 10/01/2014 10/01/2014 CPU 1 2 NSTEMI 1 1 2 1 1, ACS 2 2
75 779922F 51 M 10/01/2014 11/01/2014 CCU 1 2 AWMI I 1 1 2 2 1 2 2 2
76 751534F 61 M 11/01/2014 12/01/2014 CPU 1 1 NSTEMI 2 2 2 2 1 2 2 2
77 751786F 34 M 13/01/2014 14/01/2014 CCU 1 1 AWMI I 2 2 2 2 1 2 2 2
78 751885F 60 M 15/01/2014 16/01/2014 CCU 2 3 NSTEMI 1 2 1 2 1 2 1 2
79 753122F 53 M 18/01/2014 19/01/2014 CCU 1 1 ASMI IV 1 1 1 2 1 2 1 2
80 713237F 59 M 19/01/2014 20/01/2014 CCU 2 3 NSTEMI 2 1 2 2 2 2 2 2
81 753181F 42 M 19/01/2014 20/01/2014 CPU 1 1 AWMI I 2 2 1 2 2 2 2 2
82 709015F 54 M 20/01/2014 20/01/2014 CPU 1 1 AWMI I 2 2 1 2 1 2 2 2
83 753193F 44 M 19/01/2014 20/01/2014 CPU 1 1 AWMI II 2 2 1 2 2 2 2 2
84 753455F 57 M 22/01/2014 23/01/2014 CCU 1 2 IWMI I 1 1 2 2 1 2 2 2
85 753174F 81 M 23/01/2014 24/01/2014 CCU 1 2 NSTEMI 1 1 2 2 1 2 1 2
86 520229B 75 M 22/09/2014 23/09/2013 CCU 1 1 NSTEMI 1 1 1 2 1 1, ACS 1 2
87 922350F 55 M 18/09/2014 19/09/2014 CCU 1 1 NSTEMI 1 2 1 2 1 2 2 2
88 922802F 64 M 25/09/2014 25/09/2014 CPU 1 1 NSTEMI 2 2 1 2 1 2 2 2
89 923163F 65 M 01/10/2014 01/10/2014 CPU 1 1 NSTEMI 1 1 1 2 1 2 2 2
90 199091D 71 F 29/09/2014 30/09/2014 CPU 1 1 NSTEMI 1 1 2 1 1 1, CABG 1 2
91 505223F 42 F 07/10/2014 07/10/2014 CPU 2 3 NSTEMI 2 1 2 2 1 2 1 2
92 412556C 79 F 09/10/2014 10/10/2014 CPU 1 1 NSTEMI 1 2 2 2 1 2 2 2
93 310290C 49 M 16/10/2014 16/10/2014 CPU 1 1 AWMI 1 1 1 2 1 2 2 2
94 926377F 60 M 17/10/2014 17/10/2014 CPU 1 2 NSTEMI 2 2 2 2 2 2 2 2
95 926356F 62 M 17/10/2014 17/10/2014 CPU 1 2 IWMI I 2 2 1 2 1 2 2 2
96 116703F 59 M 17/10/2014 17/10/2014 CPU 1 1 AWMI I 2 1 1 2 1 1 2 2
97 928556F 55 F 30/10/2014 30/10/2014 CPU 1 2 NSTEMI 1 2 2 2 1 2 2 2
98 928322F 83 M 27/10/2014 28/10/2014 CCU 1 1 NSTEMI 1 2 2 2 1 1 1 2
99 928434F 70 F 29/10/2014 29/10/2014 CPU 1 2 NSTEMI 1 1 2 2 1 1 2 2
100 928609F 57 M 31/10/2014 31/10/2014 CPU 1 1 NSTEMI 2 2 2 2 2 2 2 2
101 929351F 74 M 09/11/2014 09/11/2014 CCU 2 3 NSTEMI 1 1 1 2 2 2 1 2
SN HOSP NO
IF 
INTUBATED-
PEEP
Hb HCT TLC Na K S.CREATININE B.UREA
LIPID 
PROFILE TG HDL LDL NON HDL C.
GRBS AT 
ADMISSION CKMB1 CKMB2 TROP T1 TROP T2
ECG AT 
ADM ECHO
1 713702F 9.4 30.4 12800 135 4.6 1.07 21 193 148 33 151 160 126 18.24 216.4 190.8 8845 2 2
2 713701F 13.7 35.9 11900 139 3.6 1.33 36 156 83 34 113 122 186 4.1 376.5 50.77 >10,000 2 2
3 713709F 14.4 42.7 12300 124 3.8 0.71 25 117 95 31 80 86 147 6.31 29.76 68.19 1516 2 2
4 708552F 9 27 15500 126 4.7 1.67 37 94 113 34 42 52 190 1.96 3.02 23.03 68.03 2 2
5 713710F 12.4 39.1 12100 139 3 1 26 110 4.27 14.91 20.5 1213 2 2
6 159355F 14.5 43.8 8600 141 3.5 1.3 15 221 156 32 165 189 90 4.78 324.4 36.04 >10,000 2 2
7 713756F 10.7 33 12100 128 4.9 1.16 48 163 144 36 112 127 221 11.39 10.54 414.1 815.1 2 2
8 649442C 14.9 46.3 26900 131 5.1 1.51 40 166 198 27 109 139 108 10.31 100.2 217.1 7408 2 2
9 569119B 14.5 42.7 8900 133 3.7 1.07 19 224 72 39 172 185 140 13.82 102.8 52.51 139.8 2 2
10 720081F 14.3 42.4 14500 134 1.17 13 98 427.2 171.3 3853 >10000 2 2
11 275103D 15 44.2 17000 138 3.4 1.14 17 200 115 38 150 162 68 10.28 500 69.78 6330 2 2
12 720101F 12.2 36 21100 133 3.3 1.31 19 90 23.06 357.3 31.65 >10000 2 2
13 121465B 12.7 38 14300 134 4.5 1.03 21 211 176 46 148 165 126 27.99 49.23 324.5 937 2 2
14 720097F 15.3 46 13100 129 4.6 1.32 34 208 156 33 169 175 201 8.5 29.82 77.19 468.9 2 2
15 720143F 14.5 42.3 17800 133 4.1 1.15 17 132 62 33 102 99 210 7.76 59.55 61.34 4262 2 2
16 720130F 15.4 46 7000 136 3.4 1.25 44 174 61 45 128 129 128 4.7 >500 8.28 >10000 2 2
17 903164C 14.2 42.6 8100 134 4.3 1.15 17 138 77 26 98 112 110 18.69 19.26 283.4 315.4 2 2
18 720179F 13.4 40 11000 136 3.9 1.14 160 104 40 107 120 78 89.06 119.3 1029 2 2
19 510679B 17.7 53 14300 135 3.6 1.07 21 150 4.41 114.2 21.87 280 2 2
20 623867F 11.6 34.8 135 4.6 1.08 30 214 98 40 160 174 126 12.78 17.06 355.9 393.2 2 2
21 720649F 18.1 54 9200 137 4.3 0.77 18 241 223 39 164 202 126 6.92 88.45 43.84 396.9 2 2
22 655540F 10 13 41.5 9800 117 5.1 1.87 68 130 27.62 33 110.5 119 2 2
23 720623F 13.5 41.6 12000 135 3.8 1.26 23 142 99 33 86 109 138 115 53.45 1254 7374 2 2
24 720624F 14.8 44.2 9200 136 3.6 1.19 34 126 64 37 81 89 160 43.8 124.9 281 >10000 2 2
25 294719B 14.9 43.9 10500 135 3.6 1.24 19 154 171 43 98 111 100 5.92 5.84 310.5 205.7 2 2
26 720735F 12.8 37.6 15800 133 3.5 0.83 28 152 78 36 110 116 120 26 27.86 2583 2859 2 2
27 720769F 10.3 30.7 12800 132 4.4 0.78 18 169 61 45 112 124 198 61.89 1001 2 2
28 720731F 11.2 37.3 15300 138 4.3 1.52 34 174 149 40 119 134 140 >500 >500 >10000 >10000 2 2
29 408888D 11.6 33.6 11500 135 3.7 1.08 160 116 34 124 126 206 2.99 219.8 3.01 5276 2 2
30 151157D 12.9 39.4 10300 137 3.8 0.73 24 146 90 41 99 105 246 2.94 10.07 31.26 127.7 2 2
31 622344F 13.1 39.3 13900 133 3.5 0.8 29 216 148 33 162 183 119 90.58 128 749.5 2015 2 2
32 791763B 13 39 21200 130 3.7 1.47 29 152 137 46 80 70 160 3.52 5 33.17 183.9 2 2
33 384654F 12.6 36.5 20200 132 4.1 1.22 24 140 122 37 94 103 505 6.62 10.47 21.67 119.5 2 2
34 720801F 13 40.2 17800 130 4.4 1.47 37 162 136 42 107 120 252 5.59 206.2 47.53 >10000 2 2
35 740095F 15.2 41.8 16800 138 3.9 0.62 30 183 47 73 106 110 138 76.43 >500 753 >10000 2 2
36 740214F 12.8 39 16800 135 3.9 1.08 31 127 94 28 79 99 126 45.6 17.77 3258 4251 2 2
37 726959F 13 39.2 14600 134 4.4 1.25 23 115 60 35 74 80 110 8.13 423.5 3917 2 2
38 726987F 13.7 41 15700 134 5.2 0.99 35 150 40 46 108 104 118 >500 22.11 3898 6956 2 2
39 740235F 17 51 7900 3.7 0.7 228 94 57 150 171 116 14.14 89.51 113.8 634.8 2 2
40 740247F 15.2 46 25000 138 4.3 1.29 47 197 137 48 123 149 122 59.37 77.45 1602 2547 2 2
41 824266C 18.4 53 8200 4.1 0.77 14 183 102 46 123 137 132 5.7 4.32 317 480 2 2
42 740625F 15.4 45.3 14300 136 3.3 0.87 26 185 143 25 137 160 162 213 108.5 5092 1436 2 2
43 893481C 14.8 43.6 15500 138 5.4 1.05 20 189 173 37 130 162 150 32.06 25.04 652.6 534.6 2 2
44 740651F 16.5 49.4 21700 137 4.1 1.02 23 153 84 34 104 119 126 31.15 231.1 529.9 9673 2 2
45 743754F 14.4 43.2 9400 136 3.4 1.2 32 137 111 31 92 106 145 4.75 16.69 17.55 107.4 2 2
46 740757F 9 25.4 12100 133 4.3 1.1 29 115 147 23 70 92 210 29.83 25.71 1533 1872 2 2
47 740761F 12.2 36.3 9700 135 3.6 0.74 21 184 155 47 116 137 333 8.63 13.29 238.1 492.2 2 2
48 740336F 18.6 53.6 14500 125 3.9 0.77 13 147 168 31 98 116 368 2.8 60.96 11.05 1467 2 2
49 750456F 15.2 45.7 17200 139 3.5 0.97 21 184 97 42 128 142 122 18.2 >500 285.4 >10000 2 2
50 750448F 15.1 45 9600 130 4.1 0.73 25 142 142 46 81 98 337 428 >10000 6233 2 2
51 750500F 11.9 34 12200 137 3.4 1.01 20 206 112 30 156 176 132 9.83 28.78 403.9 1211 2 2
52 744347D 12.3 46 9300 135 3.9 0.75 23 133 205 39 82 94 302 4.8 6.29 51.28 105.4 2 2
53 750411D 14.9 42.3 13000 131 3.6 0.85 19 179 120 39 121 140 256 8.52 93.61 94.75 6967 2 2
54 720775F 16.2 47 13900 141 3.8 0.76 14 166 152 40 113 126 111 6.47 173.7 85.29 7290 2 2
55 180276F 10.6 32 13100 137 4.7 1.44 64 183 86 28 130 155 108 10.2 109 97.5 400.7 2 2
56 591988C 15.3 42.1 7100 140 4.6 0.85 32 162 190 33 106 129 102 5.29 6.56 133.1 174.7 2 2
57 750175F 11.3 34.5 14100 135 4.1 0.7 18 179 71 54 124 127 210 18 22.96 157.7 310.2 2 2
58 448582F 15.4 45 131 4.9 0.95 164 124 44 108 120 233 145.2 173.3 988.1 >10000 2 2
59 039957D 10.4 31.2 12400 139 4 1.09 25 172 135 65 100 107 110 3.84 23.83 24.44 559.6 2 2
60 750726F 13 39 15900 137 3.8 1.34 27 55 54 33 17 38 188 0.24 15.48 35.55 239.9 2 2
61 332918B 11.6 32.6 8400 130 4.2 1.02 28 125 47 45 74 80 108 66.53 76.98 398.8 640.8 2 2
62 750255F 8 8.5 26.4 16100 136 3.5 0.73 38 110 134 25 61 90 330 4.66 13.87 36.5 1882 2 2
63 751213F 12 36.9 11800 140 3.9 0.92 33 248 190 36 182 212 210 2.35 148.4 32.9 6742 2 2
64 062059F 13.1 38.6 7700 139 3.5 0.87 24 186 62 48 123 138 98 2.78 205.6 12.95 4254 2 2
65 751272F 8.6 19.8 13500 134 4.1 1.47 28 105 65 25 67 80 110 22.06 215.1 274.4 9049 2 2
66 570803D 14.6 42.9 18000 132 3.7 0.87 23 176 153 44 108 132 214 3.39 182.1 24.85 4368 2 2
67 984562D 12.2 46 17500 136 4.5 1.37 27 184 169 36 122 148 289 18.81 268.2 191 >10000 2 2
68 750818F 12.5 37 10000 135 3.6 0.9 20 117 65 33 79 84 103 64.69 46.07 2098 2131 2 2
69 751298F 15.6 45 18500 135 3.7 1.16 47 186 137 37 122 149 254 190.3 175.2 863.7 4370 2 2
70 166379F 10.7 33.2 11300 137 4.1 0.71 19 133 115 55 74 89 301 4.89 8.36 21.1 63.32 2 2
71 243871C 13 38.2 22900 138 4.7 0.92 47 202 52 41 153 161 128 3.9 114.5 64.66 1956 2 2
72 751467F 11.7 34.4 10500 140 3.1 0.9 33 202 132 38 148 164 201 2.53 5.36 21.82 110.8 2 2
73 423954C 13 39.8 8800 137 3.7 0.6 18 134 138 26 90 108 186 24.07 53.68 379.2 1917 2 2
74 209951D 14 42 9300 138 4.4 0.91 19 195 144 34 133 161 201 8.21 18.54 156.7 206.5 2 2
75 779922F 12.4 36.4 11600 136 3.5 0.96 24 149 128 24 92 15 188 4.22 7.81 2227 2262 2 2
76 751534F 14.3 42.6 13700 139 4.3 0.95 30 154 135 28 102 136 98 55.28 114 629.9 1656 2 2
77 751786F 15.3 46 9800 135 3.5 1.06 26 177 60 39 125 138 93 48.76 109 443.5 7856 2 2
78 751885F 15.5 44.8 23200 128 5 1.61 40 133 58 32 93 101 112 4.74 29.02 151.7 629.7 2 2
79 753122F 13.5 39.9 15100 127 4 1.51 51 125 117 29 80 96 239 16.12 17.67 2054 1543 2 2
80 713237F 11.9 36.9 18400 133 4.3 0.91 25 108 92 43 46 65 93 6.86 7.96 123.9 214.1 2 2
81 753181F 13.3 39.6 7300 133 4.5 0.66 25 151 86 43 103 108 88 419.9 113.9 >10000 8562 2 2
82 709015F 14.3 42 9300 137 3.9 0.93 19 185 96 31 134 154 102 3.72 51.88 42.77 1299 2 2
83 753193F 16.2 48 26700 109 4.3 0.88 25 144 83 46 93 98 301 >500 >500 >10000 9502 2 2
84 753455F 15.6 46 16000 129 3.5 0.66 22 131 125 31 87 100 89 277 230 802.8 4392 2 2
85 753174F 11.3 31.4 17300 128 4.5 1.69 65 125 93 39 69 86 111 47.53 13.24 1227 1749 2 2
86 520229B 14.2 43 12500 133 4.3 1.37 26 127 106 34 77 93 137 8.58 7.44 170.2 203.2 2 2
87 922350F 14.9 43 11680 135 4.4 1.03 32 149 103 25 108 124 120 4.33 4.13 42.39 49.25 2 2
88 922802F 14.3 43.6 14400 134 3.9 0.94 36 126 45 36 78 90 112 >300 87.13 2050 5423 2 2
89 923163F 12.2 36.5 13700 133 4.2 0.97 27 150 195 27 94 123 134 3.59 8.86 120 317.6 2 2
90 199091D 9.7 29 17500 132 4.3 1.26 38 184 82 36 144 148 244 37.44 59.33 1521 8119 2 2
91 505223F 11.4 33.8 16000 133 4.4 1.57 64 68 129 11 47 19 223 6.61 8.02 2580 1776 2 2
92 412556C 12.6 38.7 7600 135 4.5 0.67 19 253 248 43 192 210 190 3.76 41.38 151.6 2 2
93 310290C 13.7 41.5 15100 133 3.7 0.77 17 210 5.35 3 190.4 461.3 2 2
94 926377F 12.6 36.8 9400 133 3.9 0.87 22 131 91 29 81 102 110 2.81 89.53 8.53 60.89 2 2
95 926356F 13 38.8 10900 139 3.9 0.69 34 152 96 32 97 120 108 >300 214.5 4315 5908 2 2
96 116703F 9.3 28.4 3500 4.5 1.1 28 177 97 32 120 145 128 2.41 28.86 54.03 711.6 2 2
97 928556F 13.7 39.8 8300 134 4 0.83 35 245 140 48 175 197 140 5.8 40.4 143.7 2 2
98 928322F 8.5 26.1 14300 132 4.6 1.49 90 102 84 30 55 72 201 10.78 12.31 434.6 452.5 2 2
99 928434F 13 40.4 9880 137 4.2 0.75 30 154 124 40 90 114 202 18.59 15.77 247.3 234.2 2 2
100 928609F 12.6 39.4 7550 141 4.3 1.18 22 152 66 47 94 105 110 3.82 5 31.1 60 2 2
101 929351F 10.5 31.6 13000 128 6.4 2.11 59 157 140 37 94 120 212 4.11 5.81 91.14 371.9 2 2
SN HOSP NO CAG
SVD (1), DVD 
(2), TVD (3), LM 
(4)
FINAL DIAGNOSIS STEMI (1)/ NSTEMI(2)
URGENT 
REVASCULARISATIO
N
INHOSPITAL 
MORTALITY
OUTCOME ≤30 DAYS AFTER 
DISCHARGE-(1)-MOR, 
(2)REHOSPITAL, (3)- Rein (4)- 
NONE  (5) IN Hosp Dth
≤30 DAY 
MORTALITY
THROM(1) / 
NONTHROM (2)
1 713702F 1 2 IWMI 1 1 2 4 2 1
2 713701F 1 4,3 AWMI 1 1 2 4 2 1
3 713709F 1 1 IWMI,PWMI,RVMI 1 1 2 4 2 1
4 708552F 1 4,3 CAD-TVD, NSTEMI 2 2 2 4 2 1
5 713710F 2 IWMI,RVMI 1 2 2 4 2 1
6 159355F 1 1 IWMI,RVMI,PWMI 1 1 2 4 2 1
7 713756F 2 NSTEMI 2 2 2 4 2 1
8 649442C 2 ASMI 1 2 2 4 2 1
9 569119B 1 3 NSTEMI 2 2 2 4 2 1
10 720081F 2 AWMI 1 2 2 4 2 1
11 275103D 1 1 AWMI 1 1 2 4 22 1
12 720101F 2 IWMI 1 2 2 4 2 1
13 121465B 1 1 NSTEMI 2 1 2 4 2 1
14 720097F 1 3 NSTEMI 2 1 2 4 2 1
15 720143F 1 1 AWMI 1 1 2 4 2 1
16 720130F 1 1 AWMI 1 1 2 4 2 1
17 903164C 1 1 NSTEMI 2 1 2 4 2 1
18 720179F 1 2 AWMI 1 1 1 4 2 1
19 510679B 1 1 AWMI 1 1 2 4 2 1
20 623867F 2 NSTEMI 2 2 2 4 2 1
21 720649F 2 NSTEMI 2 2 2 4 2 1
22 655540F 1 (OUTSIDE) 3 NSTEMI 2 2 2 1 1 1
23 720623F 1 2 AWMI 1 1 2 4 2 1
24 720624F 1 1 IWMI, RVMI 1 1 2 4 2 1
25 294719B 2 NSTEMI 2 2 2 4 2 1
26 720735F 1 2, 4 AWMI 1 1 2 4 2 1
27 720769F 2 IWMI, RVMI, PWMI 1 2 2 4 2 1
28 720731F 1 1 IWMI, PWMI 1 1 2 4 2 1
29 408888D 1 1 AWMI 1 1 2 4 2 1
30 151157D 1 3 IWMI, RVMI, PWMI 1 1 2 4 2 1
31 622344F 1 3 IWMI 1 1 2 4 2 1
32 791763B 2 NSTEMI 2 2 2 4 2 1
33 384654F 1 (OUTSIDE) 1 NSTEMI 2 2 2 4 2 1
34 720801F 1 1 AWMI 1 2 2 4 2 1
35 740095F 2 AWMI 1 2 2 4 2 1
36 740214F 1 1 AWMI 1 1 2 4 2 1
37 726959F 1 1 AWMI 1 1 2 4 2 1
38 726987F 1 1 AWMI 1 1 2 4 2 1
39 740235F 1 2 NSTEMI 2 2 2 4 2 1
40 740247F 1 3 NSTEMI 2 2 2 4 2 1
41 824266C 1 1 LATERAL MI 1 1 2 4 2 1
42 740625F 1 1 IWMI, PWMI 1 1 2 4 2 1
43 893481C 1 1 IWMI 1 1 2 4 2 1
44 740651F 1 2 AWMI 1 1 2 4 2 1
45 743754F 1 1 NSTEMI 2 2 2 4 2 1
46 740757F 1 2 IWMI 1 1 2 4 2 1
47 740761F 1 MINOR CAD NSTEMI 2 2 2 4 2 1
48 740336F 1 1 IWMI, RVMI, PWMI 1 1 2 4 2 1
49 750456F 2 AWMI 1 2 2 4 2 1
50 750448F 1 3 AWMI 1 1 2 4 2 1
51 750500F 1 1 AWMI 1 1 2 4 2 1
52 744347D 2 2 NSTEMI 2 2 2 4 2 1
53 750411D 1 1 AWMI 1 1 2 4 2 1
54 720775F 1 1 AWMI 1 1 2 4 2 1
55 180276F 2 NSTEMI 2 2 2 4 2 1
56 591988C 2 NSTEMI 2 2 2 4 2 1
57 750175F 2 NSTEMI 2 2 2 4 2 1
58 448582F 1 3 STEMI 1 1 2 4 2 1
59 039957D 1 3 NSTEMI 2 2 2 4 2 1
60 750726F 1 3 NSTEMI 2 2 2 4 2 1
61 332918B 1 3 NSTEMI 2 1 2 4 2 1
62 750255F 2 IWMI 1 2 2 4 2 1
63 751213F 1 3 IWMI,RVMI 1 1 2 4 2 1
64 062059F 2 AWMI 1 2 2 4 2 1
65 751272F 2 NSTEMI 2 2 2 4 2 1
66 570803D 1 1 IWMI 1 1 2 4 2 1
67 984562D 1 3 IWMI 1 1 2 4 2 1
68 750818F 1 3 IWMI 1 2 2 4 2 1
69 751298F 1 2 IWMI, RVMI 1 1 2 4 2 1
70 166379F 1 3 NSTEMI 2 1, CABG 2 4 2 1
71 243871C 1 1 AWMI 1 1 2 4 2 1
72 751467F 1 MINOR CAD NSTEMI 2 2 2 4 2 1
73 423954C 1 1 NSTEMI 2 1 2 4 2 1
74 209951D 1 2 NSTEMI 2 2 2 4 2 1
75 779922F 1 1 STEMI 1 1 2 4 2 1
76 751534F 1 3 NSTEMI 2 1 2 4 2 1
77 751786F 1 1 AWMI 1 1 2 4 2 1
78 751885F 2 NSTEMI 2 2 2 4 2 1
79 753122F 1 2 AWMI 1 2 2 1 1 1
80 713237F 1 3 NSTEMI 2 2 2 2 2 1
81 753181F 1 1 AWMI 1 1 2 4 2 1
82 709015F 1 3 AWMI 1 2 2 2 2 1
83 753193F 1 1 AWMI 1 1 2 4 2 1
84 753455F 1 1 IWMI 1 1 2 4 2 1
85 753174F 2 NSTEMI 2 2 2 1 1 1
86 520229B 1 3 NSTEMI 2 1 , CABG 2 4 2 1
87 922350F 1 2 NSTEMI 2 1 2 4 2 1
88 922802F 1 4 NSTEMI 2 2 2 4 2 1
89 923163F 1 1 NSTEMI 2 1 2 4 2 1
90 199091D 1 3,4 NSTEMI 2 2 2 4 2 1
91 505223F 2 NSTEMI 2 2 1 5 2 1
92 412556C 2 NSTEMI 2 2 2 4 2 1
93 310290C 1 2 AWMI 1 1 2 4 2 1
94 926377F 1 1 NSTEMI 1 2 2 4 2 1
95 926356F 1 2 IWMI 1 1 2 4 2 1
96 116703F 1 3 AWMI 1 1 2 4 2 1
97 928556F 1 1 NSTEMI 2 1 2 4 2 1
98 928322F 2 NSTEMI 2 2 2 4 2 1
99 928434F 1 3 NSTEMI 2 1 2 4 2 1
100 928609F 1 3,4 NSTEMI 2 2 2 4 2 1
101 929351F 2 NSTEMI 2 2 2 4 2 1
S.N CMC                     HOSP.NO AGE
Dur.     
(days) SEX
DT. OF 
ADMISSION
DT. OF               
ENROLL PLACE
CHEST      
PAIN
TYPE OF CHEST 
PAIN TYPICAL(1)/ 
ATYPICAL(2)NA (3)
DIAGNOSIS AT ADMISSION HTN DM II SMk
HYPO 
THYRO 
IDISM
DYSLI     
PIDEMIA
PAST H/O CAD 
(ACS/CVA/ TIA)
1 662272F 55 17 F 10/11/2013 11/11/2013 MICU 2 3 HYPEROSMOLAR NON KETOTIC STATE, UTI 1 1 2 2 2 2
2 704940F 74 25 M 05/11/2014 06/11/2014 MICU 2 3 LRTI, ARDS, SEPTIC SHOCK 1 1 2 2 2 2
3 713714F 33 18 F 13/11/2013 14/11/2013 MHDU 2 3 RHD, SEVERE MS,MR, AF WITH FVR 2 2 2 2 2 2
4 700136B 80 8 M 25/11/2013 26/11/2013 MICU 2 3 ILD, PNEUMONIA, MYOCARDITIS 2 2 2 2 2 2
5 720640F 60 10 F 24/11/2013 25/11/2013 MICU 2 3 SCRUB TYPHUS, ARDS 1 2 2 2 2 2
6 305236C 77 13 M 22/11/2013 23/11/2013 MICU 2 3 ACUTE ON CHRONIC RENAL FAILURE, UROSEPSIS 1 1 2 2 1 1-CAD
7 726804F 40 20 F 08/12/2013 09/12/2013 MICU 2 3 ACUTE PULMONARY OEDEM ?CAUSE 1 2 2 2 2 2
8 740560F 65 15 F 14/12/2014 14/12/2014 MICU 1 1 ? ACS/? PE 1 1 2 2 1 2
9 761706F 67 13 M 09/12/2013 10/12/2013 MICU 1 2 CKD 1 2 2 2 2 1- CAD
10 823549D 32 4 F 24/01/2014 24/01/2014 MICU 2 3 AGE WITH SHOCK 2 2 2 2 2 2
11 721237F 20 17 F 16/12/2013 17/12/2013 MICU 2 3 PNC DAY 1, ?ARDS, ?MYOCARDITIS 2 2 2 2 2 2
12 813874 68 17 F 17/12/2013 18/12/2013 MICU 2 3 CAD-TVD, S/P PPI FOR CHB, ACUTE ON CRF, MORBID 
OBESITY
2 1 2 2 1 1-CAD
13 740751 27 5 M 17/12/2013 18/12/2013 MHDU 2 3 ?MYOCARDITIS, MENINGOENCEPHALITIS 2 2 2 2 2 2
14 089473F 51 5 M 20/12/2013 21/12/2013 MHDU 2 3 DKA, SEPSIS, SEPTIC SHOCK, CHRONIC PANCREATITIS 2 1 1 2 2 2
15 388529F 53 5 M 22/12/2013 23/12/2013 MICU 2 3 CLL WITHFEBRILE EUTROPENIA 2 2 1 2 2 2
16 750078F 65 4 F 23/12/2013 24/12/2013 MICU 2 3 SCRUB TYPHUS, ARDS,SHOCK 2 2 2 2 2 2
17 740702F 67 30 M 16/12/2013 17/12/2013 MHDU 2 3 PNEUMONIA, COPD, LGI BLEED 1 1 1 2 2 2
18 750738F 55 24 F 31/12/2013 31/12/2013 MICU 2 3 DKA, UTI, SEPSIS, O/C IWMI 1 1 2 2 1 1-CAD
19 740939F 26 18 F 01/01/2014 02/01/2014 MICU 2 3 ACUTE PULMONARYOEDEMA, PNC DAY 1 2 2 2 2 2 2
20 949255C 32 30 F 08/01/2014 08/01/2014 MICU 2 3 UROSEPSIS, ARDS, PNC 9 DAYS 2 2 2 2 2 2
21 876069C 54 9 F 10/01/2014 10/01/2014 MICU 2 3 CKD, DKA 2 1 2 1 2 2
22 290246D 55 10 M 10/01/2014 10/01/2014 2 3 CAD, CCF 1 1 2 2 1 1-CAD
23 782649F 72 10 M 12/01/2014 13/01/2014 2 3 CHB 1 2 1 2 2 2
24 751722F 29 30 F 12/01/2014 12/01/2014 MHDU 2 3 SEPSIS, ? MENINGITIS 2 2 2 2 2 2
25 751571F 74 11 M 11/01/2014 12-Jan MHDU 2 3 SEPSIS, MODS, COPD 2 2 1 2 2 2
26 957810B 46 6 F 14/01/2014 15/01/2014 MICU 2 3 AGE WITH SHOCK, ARF 2 2 2 2 2 2
27 751841F 51 4 M 14/01/2014 15/01/2014 MICU 2 3 SCRUB TYPHUS 2 2 2 2 2 2
28 753144F 74 7 F 19/01/2014 19/01/2014 MICU 2 3 PNEUMONIA, HTN 1 2 2 2 2 2
29 890488C 67 3 F 22/01/2014 23/01/2014 2 3 CAD, CCF 1 1 2 2 1 1-CAD
30 289659C 60 11 M 19/01/2014 20/01/2014 MICU 2 3 COPD, NSTEMI 1 1 1 2 1 2
31 713588F 48 24 M 14/01/2014 15/01/2014 MICU 2 3 ALL, SIRS, SHOCK 2 2 2 2 2 2
32 308044C 74 15 M 20/01/2014 21/01/2014 MHDU 2 3 SEPSIS, SHOCK, PNEUMONIA 1 1 2 2 1 1-CAD
33 1887883D 46 15 M 16/01/2014 17/01/2014 MHDU 2 3 ARF ON CRF, DKA, SEPSIS 2 1 2 2 1 2
34 783729F 49 7 M 22/01/2014 23/01/2014 MHDU 2 3 CCF, THYROTOXICOSIS 2 2 1 2 1 2
35 199939B 77 9 M 22/01/2014 23/01/2014 MICU 2 3 COPD, PNEUMONIA, SHOCK 1 1 1 2 2 1- CAD
36 753753F 75 31 F 27/01/2014 27/01/2014 MHDU 2 3 ACS, PULMONARY OEDEMA, ACIDOSIS-METABOLIC 1 2 2 2 2 2
37 605557B 53 6 M 25/01/2014 26/01/2014 2 3 ACUTE PULMONARY OEDEM ?CAUSE 2 1 2 1 1 2
38 753826F 63 9 M 28/01/2014 29/01/2014 MHDU 2 3 SCRUB TYPHUS, ARDS 1 1 1 2 1 2
39 896263D 63 18 M 27/01/2014 27/01/2014 MICU 2 3 CKD-V, PNEUMONIA 1 1 2 2 1 2
40 785276 69 27 M 16/01/2014 16/01/2014 MICU 2 3 NSTEMI, CCF 1 1 2 2 1 2
41 754589F 54 42 F 08/02/2014 09/02/2014 MICU 2 3 AIDP, RESPIRATORY FAILURE 2 2 2 1 2 2
42 753994F 61 15 F 05/02/2014 06/02/2014 MHDU 2 3 SEPSIS, CARDIAC ARREST, SHOCK 1 1 2 2 2 2
43 784167F 49 52 F 13/02/2014 13/02/2014 MICU 2 3 SEPSIS, SHOCK 1 2 2 2 2 2
44 789657F 59 7 M 29/01/2014 29/01/2014 MHDU 2 3 SEPSIS, ARF 1 1 1 2 1 2
45 759299F 69 11 F 11/03/2014 11/03/2014 MHDU 1 1 NSTEMI, CCF 1 1 2 2 1 2
46 594716D 75 12 M 3/03/201 04/03/2014 MHDU 2 3 PNEUMOIA, SHOCK, COPD 2 1 1 2 1 2
47 813883F 74 9 M 10/03/2014 11/03/2014 MHDU 1 2 NSTEMI, SEPTIC SHOCK 1 2 2 2 1 1- CAD
48 759379F 57 27 M 12/03/2014 13-Mar MICU 2 3 DCLD, POHTN,CAD 2 1 2 2 2 1-CAD
49 850924D 67 6 M 16/03/2014 16/03/2014 MICU 1 1 CVA, PULMONARY OEDEMA 1 1 1 2 1 1-CVA
50 261226C 68 21 M 15/03/2014 15/03/2014 MICU 2 3 CA LUNG, ?ACS 1 1 1 2 1 2
51 759519F 46 6 F 15/03//2014 15/03/2014 MHDU 2 3 DCMY CARDIOGENIC SHOCK 2 2 2 2 2 2
52 448884F 24 32 F 23/03/2014 24/03/2014 MICU 2 3 SLI, CNS LUPUS, NEPHRITIS 2 2 2 2 2 2
53 901238F 30 7 F 27/03/2014 27/03/2014 MICU 2 3 MORBID OBESITY, OSA 2 2 2 2 2 2
54 875664D 67 10 M 27/03/2014 27/03/2014 MHDU 2 3 CARDIAC ARREST, SEVERE AS, AR 1 2 1 2 2 2
55 759769F 71 9 M 30/03/2014 31/03/2014 MICU 2 3 UROSEPSIS, ANAEMIA 2 1 2 2 2 2
56 901125F 53 9 F 30/03/2014 30/03/2014 MICU 2 3 ACUTE PULMONARY OEDEM ?CAUSE 2 2 2 2 2 2
57 222689B 80 16 F 03/04/2014 03/04/2014 MICU 2 3 CKD, AGE, ARF 1 1 2 2 2 2
58 896168B 67 16 M 30/03/2014 30/03/2014 MHDU 2 3 PULMONARY OEDEMA 1 1 2 2 1 1-CAD
59 829444F 53 4 M 05/04/2014 06/04/2014 MICU 2 3 CARDIAC SRREST, CAD, CKD 1 1 2 2 1 1-CAD
60 901844F 18 6 F 09/04/2014 09/04/2014 MICU 2 3 PARTIAL HANGING 2 2 2 2 2 2
61 901173F 66 18 F 31/03/2014 01/04/2014 MHDU 1 2 CAP, SEPSIS, SHOCK 2 1 1 2 1 2
62 292927 78 8 F 05/04/2014 06/04/2014 MICU 2 3 ILD, ACS 1 1 2 2 1 1-CAD
63 901914F 29 6 M 10/04/2014 10/04/2014 MHDU 2 3 SNAKE BITE, ARF 2 2 2 2 2 2
64 817024F 48 12 F 11/04/2014 11/04/2014 MICU 2 3 MULTIPLE MYELOMA, LRTI 2 2 2 2 2 2
65 989990C 74 8 F 16/04/2014 16/04/2014 MICU 2 3 NSTEMI 2 2 2 2 2 2
66 902088F 75 13 M 13/04/2014 13/04/2014 MICU 2 3 COPD, CAP, AF 1 1 1 2 1 2
67 728679F 50 2 F 18/04/22014 18/04/2014 MHDU 2 3 ?AMYLOIDOSIS, CARDIAC ARREST 1 2 2 2 2 2
68 902424F 50 8 M 19/04/2014 19/04/2014 MHDU 2 3 CAP 1 2 1 2 2 2
69 983853D 57 13 F 19/04/2014 20/04/2014 MHDU 2 3 NSTEMI 1 1 2 2 1 2
70 743464D 38 8 M 25/04/2014 25/04/2014 MHDU 2 3 HEMMORRHAGIC STROKE 1 2 2 2 2 2
71 502643F 64 25 M 23/04/2014 24/04/2014 MHDU 2 3 ANAEMIA, GI MALIGNANCY 2 2 1 2 2 2
72 910746F 25 18 F 25/06/2014 25/06/2014 MICU 2 3 PERIPARTUM CARDIOMYOPATHY 1 2 2 2 2 2
73 509840C 63 4 M 03/07/2014 03/07/2014 MICU 1 2 ACUTE PULMONARY OEDEMA 1 1 2 2 1 1
74 858816A 59 4 F 05/07/2014 05/07/2014 MICU 1 2 CKD, DM II HTN, ACUTE PULMONARY OEDEMA 1 1 2 2 1 1-CAD
75 216179D 73 11 F 02/07/2014 03/07/2014 MHDU 2 3 OP POISONING, ASPIRATION PEUMONIA 2 1 2 2 2 2
76 912219F 75 11 M 02/07/2014 02/07/2014 MICU 2 3 ACUTE FEBRILE ILLNESS 2 2 1 2 2 2
77 881568F 56 9 M 08/07/2014 09/07/2014 MHDU 2 3 CVA, MUCORMYCOIS 1 1 2 2 2 2
78 912129F 38 25 M 30/06/2014 30/06/2014 MHDU 2 2 SUPERVASMOL POISONING 2 2 2 2 2 2
79 914052F 21 7 F 16/07/2014 17/07/2014 MHDU 2 3 VIPER BITE 2 2 2 2 2 2
80 657643F 45 29 M 18/07/2014 18/07/2014 MICU 2 3 EPHROPATHY, RESPIRATORY FAILURE 2 2 1 2 2 2
81 914004F 78 16 M 21/07/2014 22/07/2014 MHDU 2 3 DELIRIUM, IGA NEPHROPATHY 2 2 2 2 2 2
82 914041F 64 18 M 17/07/2014 17/07/2014 MHDU 2 3 UTI, UROSEPSIS, CKD 1 1 2 2 1 1-CAD
83 008830G 70 20 F 24/07/2014 24/07/2014 MICU 2 3 PUO, PULMONARY OEDEMA 1 2 2 2 2 2
84 914547F 50 7 F 24/07/2014 24/07/2014 MHDU 2 3 COPD, AKI, DM II 2 1 2 2 2 2
85 914852F 38 7 F 28/07/2014 28/07/2014 MHDU 2 3 SCRUB TYPHUS,ARDS, AKI 2 2 2 2 2 2
86 376245D 48 17 F 01/08/2014 01/08/2014 MICU 1 1 ILD, LUPUS NEPHRITIS 1 2 2 2 2 2
87 915301F 68 7 M 04/08/2014 04/08/2014 MHDU 2 3 HAEMOTOXIC SNAKE BITE, ASV HYPERSENSITIVITY 2 2 2 2 2 2
88 915403F 21 11 M 06/08/2014 06/08/2014 MHDU 2 3 OP POISONING 2 2 2 2 2 2
89 915900F 55 13 M 13/08/2014 14/08/2014 MHDU 1 1 NSTEMI 2 1 1 2 1 1-CAD
90 895558F 65 21 M 09/08/2014 09/08/2014 MICU 2 3 NSTEMI, PULMONARY OEDEMA 1 1 2 2 1 2
91 750969F 61 9 F 15/08/2014 15/08/2014 MHDU 2 3 UTI, SEPSIS 2 1 2 2 2 2
92 260906F 51 14 F 01/09/2014 01/09/2014 MHDU 2 3 CKD, UROSEPSIS 1 1 2 2 1 2
93 913941F 24 17 F 13/08/2014 13/08/2014 MHDU 2 3 POSTPARTUM, PPCM 2 2 2 2 2 2
94 666298D 54 11 F 25/08/2014 25/08/2014 MHDU 2 3 DCMY, LVD, DM II NEPHROPATHY 1 1 2 2 1 2
95 917841F 79 17 M 28/08/2014 28/08/2014 MHDU 2 3 CVA, ASPIRATION PNEUMONIA 1 2 1 2 1 2
96 135775D 67 8 F 17/07/2014 17/07/2014 MHDU 2 3 ACUTE PULMONARY OEDEMA 2 3 2 2 2 2
97 888205A 67 26 M 03/09/2014 03/09/2014 MHDU 2 3 SCRUB TYPHUS, ARDS, VP 2 3 2 2 2 2
98 040852G 42 29 M 06/09/2014 06/09/2014 MICU 2 3 CELLULITIS, SEPSIS,VT, CARDIAC ARREST 1 1 2 2 2
99 511979F 20 7 F 06/09/2014 06/09/2014 MHDU 2 3 PAH, PMND 1 2 2 2 2 2
100 740029F 76 4 F 07/12/2013 08/12/2013 CCU 2 3 NSTEMI 2 2 2 2 1 2
S.N CMC                     HOSP.NO
RENAL      
FAILURE
INTUBATED  
(CPAP-3)
IF 
INTUBATED -
PEEP
Hb HCT TLC Na K S.CREATININE B.UREA
GRBS AT 
ADMISSION CKMB1 CKMB2
TROP          
T1
CMC                     
HOSP.NO TROP T2
TROPONIN 
DELTA HANGE 
>20%
ECG AT 
ADMMISSION- 
NOT S/O ACS (1), 
ABNORMAL S/O 
ACS(2)
ECHO- NOT S/O 
OF ACS(1), 
ABNORMAL S/O 
ACS(2)
1 662272F 1 1 8 10.3 31 16300 133 3.2 2.02 94 1237 2.15 1.99 18.17 662272F 23 2 1 1
2 704940F 1 1 8 11.6 35 11500 128 3.8 1.75 42 201 4.86 12.51 172.6 704940F 94.83 1 1 1
3 713714F 1 1 8 13.1 39 21900 113 5.2 2 75 98 10 11 42 713714F 20 1 1 1
4 700136B 2 2 NA 13.1 40 13100 129 4.2 0.79 68 102 3.31 3.42 872.6 700136B 900.3 2 1 1
5 720640F 1 1 10 11.5 35.5 16500 137 3.8 1.46 127 108 21.3 21.46 155 720640F 167.4 2 2 1
6 305236C 1 1 7 6.1 19 7000 138 4 4.33 119 180 2.3 1.86 248.7 305236C 216.1 2 2 2
7 726804F 1 1 11 13.8 41 24300 139 3.3 1.44 33 190 15.31 36.88 229.7 726804F 774.7 1 2 2
8 740560F 2 1 10 13.2 40 14400 142 4.1 0.75 21 188 2.61 9.6 22.84 740560F 401 1 1 2
9 761706F 1 1 8 6.2 17.8 12500 122 5.9 16.92 142 210 8.82 12.16 291.7 761706F 1273 1 2 2
10 823549D 1 1 6 11 33 12000 130 3 1.66 148 1.99 13.1 8.97 823549D 121.9 1 2 2
11 721237F 2 3 8 9.7 27.3 6300 131 4.7 0.75 19 108 7.52 7.78 32.73 721237F 61.88 1 1 1
12 813874 1 1 10 9 27 11700 150 4.3 2 57 202 5.24 7.48 84.27 813874 69.44 2 1 1
13 740751 2 1 7 14.5 42 8000 131 4.1 0.8 38 118 18 22.83 600 740751 900.7 1 2 2
14 089473F 2 1 8 10.7 33 12600 164 3.6 1.21 58 176 1.26 10.63 46.95 089473F 206.1 1 2 2
15 388529F 2 2 NA 6.4 19 30500 125 4 1.19 20 90 0.859 3.29 15.68 388529F 43.68 1 2 2
16 750078F 1 1 10 12.5 35.7 5300 128 3.7 2.14 116 136 4.75 6 39.53 750078F 70 1 2 2
17 740702F 1 1 10 9.3 28.1 23400 139 4 2.32 56 166 1.93 1.98 75.89 740702F 72.26 2 1 1
18 750738F 1 2 NA 17.2 39 11000 122 3.1 1.94 34 455 54.18 252 72.33 750738F 876.1 1 2 2
19 740939F 1 1 6 8.9 28 24000 131 4.5 6.9 62 110 2.24 5 91.27 740939F 200 1 2 2
20 949255C 2 2 NA 10.9 31 15200 141 3.8 0.84 22 80 2.88 1.91 26.5 949255C 17.94 1 1 1
21 876069C 1 2 NA 8.5 25.4 6300 124 4.6 2.75 71 600 15.3 17.73 291 876069C 353 1 2 2
22 290246D 1 2 NA 12 34.7 12200 131 5 1.79 49 221 4.84 5 40.42 290246D 51.81 1 2 2
23 782649F 1 2 NA 12.8 38.2 13700 135 3.3 1.53 27 112 2.95 3.67 40.89 782649F 55.1 1 1 1
24 751722F 1 1 9 10.5 31.9 5500 134 2.8 1 16 68 5.26 7.09 81.55 751722F 74.34 2 1 1
25 751571F 2 1 8 11.7 36.8 57200 113 2.7 0.66 20 221 8 10.83 54.84 751571F 37.09 1 1 1
26 957810B 1 2 NA 10.3 30.1 6400 138 3.3 1.78 64 112 4.54 4.78 50.01 957810B 107.5 1 2 2
27 751841F 2 2 NA 14.4 39.9 13400 126 3.8 1.32 50 102 4.1 3.44 25.65 751841F 28.65 2 1 1
28 753144F 1 3 8 12.4 38.1 24600 135 3.3 1.48 31 132 6.48 6.84 75.91 753144F 81.42 2 1 1
29 890488C 1 2 NA 10.7 31.4 11900 135 5.5 1.74 35 144 3.39 3.66 42.36 890488C 43.73 2 1 1
30 289659C 1 1 8 11.4 33.6 29400 127 4.3 1.86 74 301 8 12.55 150.2 289659C 435 1 2 2
31 713588F 2 1 8 8.9 26.2 1800 116 4 0.75 112 6 6.56 22.33 713588F 23.58 2 1 1
32 308044C 1 1 7 12.2 37 7700 133 4.8 2.53 55 132 14.48 11.96 47.48 308044C 96.11 1 2 2
33 1887883D 1 1 8 8.4 26.4 11200 138 3.4 2.72 102 588 12.41 13.52 486.8 1887883D 544.9 2 2 2
34 783729F 2 2 NA 13.2 43.4 13700 142 4.6 0.69 20 112 2.61 3.6 11.02 783729F 49.56 1 1 1
35 199939B 2 2 NA 13.6 40 29700 116 3.9 1.18 22 201 27.83 17.56 66.55 199939B 48.5 1 1 1
36 753753F 2 1 9 12.6 43 14500 128 3.8 1.31 54 146 5.72 13.37 299.5 753753F 545 1 2 2
37 605557B 2 2 NA 14.8 43.6 13700 141 3.2 0.61 20 221 22.43 20.32 679.8 605557B 755.4 1 2 2
38 753826F 2 1 7 12.9 38.7 10400 121 2.7 1.03 37 144 4.85 3.96 71.6 753826F 90.97 1 1 1
39 896263D 1 1 10 10.3 30.8 31500 136 3.4 3.05 109 309 10.46 24.13 38.17 896263D 59.33 1 1 1
40 785276 1 1 7 12.7 36.2 10800 126 5.4 1.68 45 289 2.37 4.57 20.93 785276 24.8 2 2 2
41 754589F 2 1 8 13.6 40.2 21600 127 3.5 0.61 47 112 6.73 8.7 89.01 754589F 71.67 2 1 1
42 753994F 1 1 9 11.4 33 9600 137 35 2.6 33 110 1.26 1.83 57.57 753994F 53.78 2 1 1
43 784167F 1 1 7 9.1 27 24600 139 3.4 1.68 30 189 6.52 14.77 384.7 784167F 203.7 1 1 1
44 789657F 1 1 9 10.9 31 17200 132 6 3.12 188 301 1.88 2.31 35.64 789657F 49.5 1 1 1
45 759299F 2 1 8 10 29.8 30800 130 4.6 0.83 42 205 5.33 4.95 18.41 759299F 146.7 1 2 2
46 594716D 1 1 9 14.3 31.7 18600 136 4.4 1.57 65 130 34.82 29.88 709.2 594716D 2989 1 2 2
47 813883F 1 1 10 11.2 33.4 5300 151 3.3 1.83 51 112 4.13 214 14.77 813883F 2520 1 2 2
48 759379F 1 1 8 6.5 19.3 9400 116 4.2 0.82 35 98 3.8 2.89 28.87 759379F 26.8 2 1 1
49 850924D 1 1 8 12 36 17700 136 3.9 3.46 59 201 4.09 8.21 76.24 850924D 202 1 2 2
50 261226C 2 1 7 10.8 31.6 15400 130 4 0.91 64 201 8.33 4.81 94.69 261226C 216.2 1 2 2
51 759519F 2 1 10 9.6 29.5 7600 131 3 0.95 29 128 1.85 1.98 19.56 759519F 21.45 2 1 1
52 448884F 1 1 9 7.1 20.4 5800 134 3.4 5.25 194 78 2.14 2.12 229.2 448884F 192 2 1 1
53 901238F 1 1 10 12.6 38.9 18300 131 4.7 1.81 146 192 2.82 2.14 21.94 901238F 24.15 2 1 1
54 875664D 1 1 8 10.8 33.1 15600 136 5.4 2.22 53 200 6.66 16.67 71.18 875664D 164.1 1 2 2
55 759769F 1 3 7 5.7 16.4 5400 142 3 2.8 88 190 3.79 6.09 58.16 759769F <3 1 1 1
56 901125F 2 1 7 13.2 43.4 42400 137 3.8 1.08 42 112 5.66 16.04 42.55 901125F 73.7 1 1 1
57 222689B 1 2 9.4 28 10200 136 4.2 2.57 69 255 21.79 36.13 103.4 222689B 578.6 1 2 2
58 896168B 1 1 8 11.8 35.6 3300 125 4.3 1.49 43 280 1.63 1.34 17 896168B 15 2 1 1
59 829444F 1 1 8 8.3 24.8 28000 135 4.8 6.66 81 180 15.65 4.07 2062 829444F 1474 1 1 1
60 901844F 2 1 7 15.7 46.1 15700 132 3 0.96 22 121 6.94 10.24 360 901844F 284.1 1 1 1
61 901173F 1 1 8 12.8 38.2 6200 138 4 1.62 45 200 6.04 4.64 12.89 901173F 16.18 2 1 1
62 292927 1 1 6 10.7 33 2800 128 3.3 1.42 25 198 1.85 3.28 15.63 292927 32.42 1 1 1
63 901914F 1 1 7 10.4 30.5 16900 140 4.3 1.48 83 122 8.98 11.85 67.96 901914F 98.53 1 1 1
64 817024F 2 2 8.1 25 2100 132 2.6 0.49 20 132 4.96 10.85 272 817024F 671.6 1 2 2
65 989990C 2 2 12.4 36.9 9400 126 3.5 0.97 27 138 3.66 6.17 101.8 989990C 177 1 2 2
66 902088F 1 1 8 11.7 33.3 6800 135 4.1 3.5 108 142 1.74 1.56 38.22 902088F 27.94 1 1 1
67 728679F 2 1 12 11.8 35.8 13800 135 3.4 0.44 13 188 11.61 10.8 122 728679F 306.6 1 2 2
68 902424F 2 3 9 14 47 12700 121 4 1.03 34 130 6.31 7.76 31.78 902424F 20.23 1 1 1
69 983853D 2 1 7 13.1 37.2 17500 135 3.7 0.83 30 148 3.1 2.58 16.46 983853D 124.4 1 2 2
70 743464D 1 1 6 18 52.6 19900 133 3.8 1.92 29 146 31.31 21.7 423.8 743464D 552.6 1 2 2
71 502643F 1 1 8 6.1 17.8 23700 133 4.5 2.15 53 110 2 1.19 67 502643F 60 2 1 1
72 910746F 1 1 8 13.8 42.9 21350 146 4 1.55 101 188 23.1 15.54 7879 910746F 6549 2 1 1
73 509840C 1 1 8 13 39 17300 135 3.9 1.49 37 201 1.94 2.33 30.77 509840C 43.93 1 2 2
74 858816A 1 1 10 11 33 31780 125 5 2.73 68 190 35.98 35.59 7302 858816A 7431 2 2 2
75 216179D 1 1 7 17.7 53.1 22000 142 2.7 1.73 71 130 20.31 16.71 14.48 216179D 13.7 2 1 1
76 912219F 1 1 8 12.5 37.2 8400 140 4.7 4.52 184 200 36.51 23.47 20.24 912219F 17.61 2 1 1
77 881568F 2 1 8 8 24 9200 140 3.8 1.2 27 110 4.34 7 47.85 881568F 80 1 2 2
78 912129F 1 1 8 13.3 39 18050 141 3.5 4 26 176 27.78 14.69 360 912129F 1559 1 1 1
79 914052F 2 2 10.1 30.8 24900 147 3.1 1.18 62 118 45.43 19.27 651.3 914052F 503.6 2 1 1
80 657643F 1 1 7 10.6 32 23400 136 4.5 3.83 50 180 2.84 3.09 116 657643F 128.4 2 2 2
81 914004F 2 3 8 8.4 25 19000 137 3.9 0.71 55 112 2.09 2.62 1243 914004F 866.6 1 2 2
82 914041F 1 1 7 7.5 22 23500 137 5.2 5.63 194 190 2.67 2 414.5 914041F 416.7 2 2 2
83 008830G 2 1 8 11.3 33.6 33800 132 3.9 0.85 20 118 2.82 8.8 206.8 008830G 317 1 2 2
84 914547F 2 1 5 11.3 37.6 24400 131 4.6 1.28 36 110 2.39 2.09 21.94 914547F 26.6 2 1 1
85 914852F 1 1 8 9.8 28.7 15700 138 3.5 1.33 71 108 2.92 3.12 85.33 914852F 35.52 1 1 1
86 376245D 1 1 12 7.3 21.9 13000 128 5.9 2.59 81 178 1.38 4.11 32.95 376245D 336.8 1 2 2
87 915301F 2 1 8 13.8 40.2 15400 139 3.8 1.04 42 122 17.86 14.14 917.8 915301F 406.3 1 1 1
88 915403F 2 1 10 16.5 46 26600 138 3.9 1.08 22 102 12.53 12.01 251 915403F 209.8 2 1 1
89 915900F 1 2 14.5 46 18100 128 4.8 1.92 51 202 2.1 >300 37.17 915900F 3641 1 2 2
90 895558F 1 1 8 10.5 31 20100 129 3.6 1.71 30 306 2.42 39.26 57 895558F 700 1 2 2
91 750969F 1 2 8.5 25.4 9700 135 4 2.05 78 112 3.13 12.77 125 750969F 180 1 2 2
92 260906F 1 1 10 7.9 23.3 16800 133 4.3 4.75 108 174 0.709 0.832 66.99 260906F 59.9 2 1 1
93 913941F 2 2 9.2 27.5 12500 130 4.5 0.9 30 102 4.19 2.89 26.26 913941F 15.05 1 1 1
94 666298D 1 1 12 14.3 42.6 6900 113 5.1 1.75 77 98 5.7 5.07 219 666298D 182 2 1 1
95 917841F 2 1 10 10.6 31 9200 134 3.4 1.35 55 152 10.16 8 16.65 917841F 89 1 2 2
96 135775D 1 2 6.5 19 13390 142 6.6 1.54 55 124 4.85 3.74 114.4 135775D 74.13 1 1 1
97 888205A 1 1 8 9 28.6 15700 131 5 2.18 85 98 21.39 19.97 48.48 888205A 55.91 2 1 1
98 040852G 1 1 7 13.5 40.2 6100 132 4.9 1.5 28 420 4.11 2.3 110.7 040852G 106.2 2 1 1
99 511979F 2 1 4 18.4 61.2 8700 134 3.9 0.58 28 131 6.09 4.64 28.23 511979F 25.62 2 1 1
100 740029F 2 2 12.8 39 14300 133 3.6 0.59 24 223 11.04 14.91 585.8 740029F 735.2 1 2 2
S.N CMC                     HOSP.NO
APACHE II 
SCORE
Apache II score- 
12 TO 17=1, 18 
T0 24=2, ≥25=3
CAG FINAL DIAGNOSIS
URGENT 
REVASCULARISATION 
YES (1)/NO(2)
INHOSPITAL- (1)-MORTALITY , (2) 
MYOCARDIAL INFARCTION, (A)-
STEMI, (B) NSTEMI, (3) NONE
OUTCOME ≤30 DAYS AFTER 
DISCHARGE-(1)-MORTALITY, (2)- 
REHOSPITALISATION, (3)- 
REINFARCTION, (4)- NONE, (5) 
INHOSPITAL DEATH
≤30 DAY 
MORTALITY
≤30 DAY 
REHOSPITALISATION
1 662272F 24 2 2 UTI, NOSOCOMIAL PNEUMONIA, HYPEROSMOLAR ON KETOTIC STATE 2 3 4 2 2
2 704940F 34 3 2 NOSOCOMIAL PNEUMONIA, H3N1 INFECTION, TYPE I RESPIRATORY 2 1 5 2 2
3 713714F 21 2 2 RHD, SEVERE MS, MR,AF WITH FVR, LRTI 2 3 4 2 2
4 700136B 17 1 2 ARDS SECONDARY TO VIRAL MYOCARDITIS, ILD 2 1 5 2 2
5 720640F 28 3 2 ARDS, SCRUB TYPHUS,HTN 2 3 4 2 2
6 305236C 29 3 2 CKD, MRSA SEPTICEMIA, MODS, DIC 2 1 5 2 2
7 726804F 35 3 2 ACS-NSTEMI, HTN, CARDIAC ARREST 2 2B 4 2 2
8 740560F 21 2 2 NSTEMI, CARDIOGENIC SHOCK,HIE 2 1 5 2 2
9 761706F 12 1 2 CKD STAGE V, PNEUMONIA, STEMI 2 2B 4 2 2
10 823549D 18 2 2 ACS-NSTEMI, CMC MYOCARDITIS, PNEUMONIA, HIV 2 2B 1 1 2
11 721237F 12 1 2 MYOCARDITIS, ARDS 2 3 4 2 2
12 813874 36 2 2 SEPSIS, UTI 2 3 4 2 2
13 740751 23 2 2 ACS-NSTEMI,TB MENINGITIS, CVA, 2 1,2B 5 2 2
14 089473F 29 3 2 NSTEMI 2 1, 2B 5 2 2
15 388529F 27 3 2 PNEUMONIA, CLL, SEPSIS, SHOCK 2 2B 1 1 2
16 750078F 28 3 2 ACS-NSTEMI,SCRUB TYPHUS 2 1,2B 5 2 2
17 740702F 27 3 2 AF,COPD, PNEUMONIA 2 1 5 2 2
18 750738F 25 3 2 NSTEMI, SEPSIS, SHOCK, AKI 2 2B 4 2 2
19 740939F 33 3 2 ACS-NSTEMI,ARF, RENAL CORTICAL NECROSIS 2 2B 4 2 2
20 949255C 12 1 2 ARDS, UROSEPSIS 2 3 4 2 2
21 876069C 23 2 2 CKD, DKA, CCF 2 2B 4 2 2
22 290246D 23 2 2 CAD, CCF 2 3 4 2 2
23 782649F 18 2 2 CHB 2 3 4 2 2
24 751722F 17 1 2 CNS VASCULITIS, SEPSIS, ARDS, MYOCARDITIS 2 1 5 2 2
25 751571F 35 3 2 SEPSIS, SHOCK 2 1 5 2 2
26 957810B 18 2 2 SHOCK, ARF 2 2B 4 2 2
27 751841F 15 1 2 SHOCK 2 3 4 2 2
28 753144F 17 1 2 SHOCK, ARDS 2 3 4 2 2
29 890488C 23 2 2 CCF, CAD 2 3 4 2 2
30 289659C 30 3 2 COPD, NSTEMI 2 2B 4 2 2
31 713588F 23 2 2 SEPSIS, SHOCK 2 3 1 1 2
32 308044C 29 3 2 SEPSIS, SHOCK, PNEUMONIA 2 2B 4 2 2
33 1887883D 35 3 2 UTI, SEPSIS, AFR ON CRF 2 2B 4 2 2
34 783729F 12 1 2 HYPERTHYROIDISM, LVD 2 3 2 2 1
35 199939B 24 2 2 ARDS, PNEUMONIA, SEPSIS, SHOCK 2 1 1 1 2
36 753753F 22 2 2 NSTEMI, HF 2 2B 4 2 2
37 605557B 12 1 2 NSTEMI, CCF, PAPILLARY CARCINOMA THYROID 2 2B 2 2 1
38 753826F 16 1 2 SCRUB TYPHUS, LVD 2 3 4 2 2
39 896263D 37 3 2 CKD, SEPSIS, SHOCK,PNEUMONIA 2 1 5 2 2
40 785276 30 3 2 NSTEMI,SEPSIS,SHOCK 2 1 5 2 2
41 754589F 15 1 2 AIDP 2 3 4 2 2
42 753994F 30 3 2 CPR, SEPSIS, SHOCK 2 3 4 2 2
43 784167F 23 2 2 CVA, SEPSIS 2 3 4 2 2
44 789657F 32 3 2 SEPSIS, SHOCK,ARF 2 1 5 2 2
45 759299F 19 2 2 NSTEMI, CAP 2 1, 2B 5 2 2
46 594716D 28 3 2 NSTEMI 2 2B 1 1 2
47 813883F 34 3 2 STEMI, ARF 2 2A 4 2 2
48 759379F 30 3 2 DCLD, POHT, SEPSIS, ARF 2 1 5 2 2
49 850924D 33 3 2 CKD, NSTEMI 2 2B 4 2 2
50 261226C 29 3 2 NSTEMI, VAP, SEPSIS 2 2B, 1 5 2 2
51 759519F 21 2 2 DCMY, CARDIOGENIC SHOCK 2 1 5 2 2
52 448884F 28 3 2 MYOCARDITIS, LUPUS NEPHRITIS, CNS LUPUS 2 1 5 2 2
53 901238F 17 1 2 OSA, SHOCK 2 1 5 2 2
54 875664D 30 3 2 NSTEMI 2 2B 1 1 2
55 759769F 35 3 2 SEPSIS, ANAEMIA 2 3 2 2 1
56 901125F 12 1 2 RHD, SEVERE MS,PAH, LRTI 2 3 4 2 2
57 222689B 30 3 2 NSTEMI 2 2B 4 2 2
58 896168B 18 2 2 PNEUMONIA, VAP, GTCS 2 1 5 2 2
59 829444F 35 3 2 CPR, CKD 2 1 5 2 2
60 901844F 14 1 2 MYOCARDIAL STUNNING, PARTIAL HANGING 2 3 4 2 2
61 901173F 25 3 2 CAP, ARDS 2 3 4 2 2
62 292927 26 3 2 VAP, SEPSIS, SHOCK, ARDS 2 1 5 2 2
63 901914F 20 2 2 VIPER BITE 2 3 4 2 2
64 817024F 23 2 2 NSTEMI 2 2B 4 2 2
65 989990C 16 1 2 NSTEMI 2 2B 4 2 2
66 902088F 28 3 2 AF, PNEUMONIA, COPD 2 3 4 2 2
67 728679F 30 3 2 NSTEMI, CARDIOGENIC SHOCK 2 1 5 2 2
68 902424F 22 2 2 HIV, PNEUMONIA 2 3 4 2 2
69 983853D 26 3 1 NTTE, PNEUMONIA 2 3 1,2 1 1
70 743464D 23 2 2 PONTINE HEMORRHAGE 2 1, 2B 5 2 2
71 502643F 27 3 2 PROBABLE GI MALIGNANCY 2 3 4 2 2
72 910746F 18 2 2 PERIPARTUM CARDIOMYOPATHY 2 1 5 2 2
73 509840C 12 1 1 NSTEMI 2 2B 2 2 1
74 858816A 34 3 2 NSTEMI 2 1, 2B 5 2 2
75 216179D 30 3 2 ASPIRATION PNUMONIA 2 3 1 1 2
76 912219F 30 3 2 ARF, ARDS, SEPSIS 2 1 5 2 2
77 881568F 19 2 2 NSTEMI,CAVERNOUS SINUS THROMBOSIS 2 1,2B 5 2 2
78 912129F 12 1 2 RHABDOMYLYSIS, ARF 2 3 4 2 2
79 914052F 12 1 2 VIPER BITE 2 3 4 2 2
80 657643F 21 2 2 CKD, NSTEMI 2 2B 4 2 2
81 914004F 20 2 2 NSTEMI,UROSEPSIS, DELIRIUM 2 2B 4 2 2
82 914041F 31 3 2 NSTEMI,UROSEPSIS, ARF 2 2B 1 1 2
83 008830G 16 1 NSTEMI 2 2B 4 2 2
84 914547F 15 1 2 COPD, PNEUMONIA 2 3 4 2 2
85 914852F 18 2 2 SCRUB TYPHUS, ARDS, AKI 2 3 4 2 2
86 376245D 35 3 2 NSTEMI 2 2B 4 2 2
87 915301F 12 1 2 MYOCARDITIS, HAEMOTOXIC SNAKE BITE 2 3 4 2 2
88 915403F 23 2 2 OP POISONING, MYOCARDITUS 2 3 4 2 2
89 915900F 21 2 2 NSTEMI 2 2B 4 2 2
90 895558F 28 3 2 NSTEMI 2 2B 4 2 2
91 750969F 26 3 2 NSTEMI 2 2B 4 2 2
92 260906F 24 2 2 PYELONEPHRITIS, DM II 2 3 4 2 2
93 913941F 12 1 2 PPCM 2 3 4 2 2
94 666298D 29 3 2 DCMY, CKD 2 3 4 2 2
95 917841F 36 3 2 NSTEMI,CVA, AF, ASPIRATION PNEUMONIA 2 1, 2B 5 2 2
96 135775D 27 3 2 ANAEMIA, CCF 2 3 4 2 2
97 888205A 32 3 2 SRUB TYPHUS, ARDS, VAP 2 3 4 2 2
98 040852G 16 1 2 CELLULITIS, SEPSIS, CPR 2 3 4 2 2
99 511979F 27 3 2 ALS, PAH, RESPIRATORY FAILURE, POLYCYTHEMIA 2 3 2 2 2
100 740029F 20 2 1 NSTEMI 2 2B 4 2 2
S.N CMC                     HOSP.NO
TOTAL MORTALITY (IN-
HOSPITAL AND ≤30DAYS 
MORTALITY)
THROMBOTIC (1) 
/NONTHROMBOT
IC (2)
STEMI (1) 
NSTEMI(2),            
NONE (3)
CAUSE OF NON-THROMBOTIC TROPONIN 
ELEVATION CPR PNEUMONIA SEPSIS
TACHYA
RRHYTH
MIA
BRADYA
RRHYTH
MIA
MYOCAR
DITIS ARDS DKA SHOCK ARF CKD COPD CHF AIDP CVA
ANEMI
A RHD GTCS
SNAKE 
BITE
1 662272F 2 2 3 SEPSIS, PNEUMONIA, KETOSIS 2 1 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2
2 704940F 1 2 3 PNEUMONIA 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
3 713714F 2 2 3 PNEUMONIA, TACHYARRHYTHMIA, SHOCK,SEPSIS 2 1 1 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2
4 700136B 1 2 3 MYOCARDITIS, ARDS 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
5 720640F 2 2 3 ARDS, SEPSIS, SHOCK 2 2 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2
6 305236C 1 2 3 SEPSIS, ACUTE ON CKD 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2
7 726804F 2 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
8 740560F 1 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
9 761706F 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
10 823549D 1 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
11 721237F 2 2 3 MYOCARDITIS, ARDS 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2
12 813874 2 2 3 ARF, SHOCK, 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2
13 740751 1 1 2 NA 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
14 089473F 1 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
15 388529F 1 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
16 750078F 1 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
17 740702F 1 2 3 AF, COPD, PNEUMONIA, SHOCK 2 2 1 1 2 2 2 2 1 1 2 1 2 2 2 1 2 2 2
18 750738F 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
19 740939F 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
20 949255C 2 2 3 URROSEPSIS, ARDS 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 1 2 2 2
21 876069C 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
22 290246D 2 2 3 HF 2 2 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2
23 782649F 2 2 3 CHB 2 2 1 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2
24 751722F 1 2 3 SEPSIS, ARDS, MYOCARDITIS 2 2 1 2 2 1 1 2 2 1 2 2 2 2 2 1 2 2 2
25 751571F 1 2 3 SEPSIS, SHOCK 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
26 957810B 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
27 751841F 2 2 3 SHOCK 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
28 753144F 2 2 3 SHOCK, ARDS 2 2 1 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2
29 890488C 2 2 3 HF 2 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2
30 289659C 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
31 713588F 1 2 3 SEPSIS, SHOCK 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2
32 308044C 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
33 1887883D 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
34 783729F 2 2 3 HYPERTHYROIDISM, HF 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2
35 199939B 1 1 3 ARDS, PNEUMONIA, SEPSIS, SHOCK 2 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2
36 753753F 2 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
37 605557B 2 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
38 753826F 2 2 3 NA 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
39 896263D 1 2 3 CKD, SEPSIS, PNEUMONIA, SHOCK 2 1 1 2 2 2 2 2 1 1 1 2 2 2 2 1 2 2 2
40 785276 1 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
41 754589F 2 2 3 AIDP 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2
42 753994F 2 2 3 SEPSIS, SHOCK, CPR 1 2 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2
43 784167F 2 2 3 SEPSIS, CVA, ARF 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 1 2 2 2
44 789657F 1 2 3 SEPSIS, SHOCK, ARF 2 2 1 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2
45 759299F 1 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
46 594716D 1 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
47 813883F 2 1 1 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
48 759379F 1 2 3 DCLD, SEPSIS, SHOCK, ARF 2 2 1 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2
49 850924D 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
50 261226C 1 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
51 759519F 1 2 3 CARDIOGENIC SHOCK 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2
52 448884F 1 2 3 ARF, MYOCARDITIS 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 1 2 2 2
53 901238F 1 2 3 SHOCK, SEPSIS, ARF 2 2 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2
54 875664D 1 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
55 759769F 2 2 3 ANAEMIA, ARF, SEPSIS 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
56 901125F 2 2 3 SEVERE MS, PAH, PNEUMONIA 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
57 222689B 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
58 896168B 1 2 3 SEPSIS, PNEUMONIA, GTCS 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2
59 829444F 1 2 3 CPR, CKD 1 2 1 2 2 2 2 2 2 1 1 2 2 2 2 1 2 2 2
60 901844F 2 2 3 MYOCARDIAL STUNNING 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
61 901173F 2 2 3 ARDS, ARF, PNEUMONIA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
62 292927 1 2 3 ARDS, SEPSIS, SHOCK, VAP 2 1 1 2 2 2 1 2 1 1 2 2 2 2 2 1 2 2 2
63 901914F 2 2 3 MYOCARDITIS, ARF 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
64 817024F 2 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
65 989990C 2 1 2 NA 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
66 902088F 2 2 3 AF, COPD, PNEUMONIA 2 1 2 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2
67 728679F 1 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
68 902424F 2 2 3 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
69 983853D 1 2 3 PNEUMONIA,ARDS, SEPSIS,SHOCK 2 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2
70 743464D 1 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
71 502643F 2 2 3 ANAEMIA, ARF, SEPSIS 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
72 910746F 1 2 3 PERIPARTUM CARDIOMYOPATHY 2 2 1 2 2 1 2 2 2 1 2 2 1 2 2 2 2 2 2
73 509840C 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
74 858816A 1 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
75 216179D 1 2 3 PNEUMONIA 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
76 912219F 1 2 3 ARF, ARDS, SEPSIS 2 2 1 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2
77 881568F 1 1 2 NA 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
78 912129F 2 2 3 ARF 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
79 914052F 2 2 3 HEMOTOXIC SNAKE BITE 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 1
80 657643F 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
81 914004F 2 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
82 914041F 1 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
83 008830G 2 1 2 NA 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
84 914547F 2 2 3 PNEUMONIA, SEPSIS 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
85 914852F 2 2 3 ARDS, AKI 2 1 1 2 2 2 1 2 2 1 2 2 2 2 2 1 2 2 2
86 376245D 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
87 915301F 2 2 3 MYOCARDITIS, HAEMOTOXIC SNAKE BITE 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
88 915403F 2 2 3 OP POISONING, CARDIAC ARREST, MYOCARDITIS 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
89 915900F 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
90 895558F 2 1 2 NA 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
91 750969F 2 1 2 NA 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
92 260906F 2 2 3 PYELONEPHRITIS, UROSEPSIS, CKD 2 1 1 2 2 2 2 2 2 1 1 2 2 2 2 1 2 2 2
93 913941F 2 2 3 PPCM 2 2 1 2 2 1 2 2 2 2 2 2 1 2 2 1 2 2 2
94 666298D 2 2 3 DCMY, CKD 2 2 2 2 2 2 2 2 2 1 1 2 1 2 2 2 2 2 2
95 917841F 1 1 2 NA 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
96 135775D 2 2 3 ANAEMIA,ARF 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
97 888205A 2 2 3 SCRUB TYPHUS, ARDS, VAP 2 1 1 2 2 2 1 2 2 1 2 2 2 2 2 1 2 2 2
98 040852G 2 2 3 CPR, VT, ARF 1 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
99 511979F 2 2 3 ALS, PAH 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2
100 740029F 2 1 2 NA 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
